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ABSTRACT OF THE DISSERTATION

The Effect of Radiation and Repeated Sub-culturing on TGF-pl Signaling in
FRTL-5 Cells
by
Cheryl G. Burrell
Doctor of Philosophy, Graduate Program in Microbiology and Molecular Genetics
Loma Linda University, May 2007
Dr. Lora Green, Chairperson.

From our ongoing in vitro studies using the Fisher Rat Thyroid cell line-5 (FRTL5) we recorded accelerated growth, reduced follicularization and reduction in thyroxin
release that occurred as the cells were repeatedly sub-cultured. We also recorded that
these changes occurred earlier and more rapidly following radiation exposure.

We

determined that TGF-pi production increased under both conditions. We hypothesized
that alteration in the TGF-(31 signaling pathway contributed to the changes observed in
the cellular properties of FRTL-5 cells. Our objective was to examine some of the players
in the TGF-(31 signaling pathway to determine whether radiation and/or repeated sub
culturing promoted changes in their levels and/or activity.
We quantified changes in cellular growth rate using the MTS cell proliferation
assay.

TGF-(31

ligand

and

receptor

levels

were

quantified

via

ELISA,

immunocytochemistry and western blot analysis respectively. The levels and activity of
Smads 2, 3, 4 and 7, downstream effectors in the TGF-J31 signaling pathway were also
measured via western blotting.

Lastly, we examined whether TGF-(31 was correctly

regulating the expression of its response genes; cyclin A and plasminogen activator
inhibitor-1 (PAI-1) under our experimental conditions. To determine this we used

xv

luciferase reporter constructs containing promoters for cyclin A and PAI introduced to
the cultures by transfection. PAI-1 production in response to exogenously added TGF-P
was also tested using a PAI-1 specific ELISA.
We observed an acceleration of growth that occurred earlier in irradiated cells
than it did in cells subjected to repeat sub-culturing (p < 0.05). The TGF-P 1 receptor
levels remained unchanged as a result of radiation and continual passage. We, however,
observed decreases in the TGF-P 1 induced phosphorylation levels of Smads2 (p < 0.05)
and 3 (p < 0.05) after radiation and repeated subculturing. However, no differences in the
inherent un-activated levels of Smads2, 3, 4 and 7 were observed. Alterations were
observed in TGF-P 1 ability to control the expression of cyclin A and PAI-1.
Collectively, these results support that alterations in the TGF-P 1 signaling
pathway were contributing to the changes in cellular properties that we measured in our
cell line, FRTL-5. These alterations were evident at the level of Smad signaling and
transcription initiation.

xvi

CHAPTER ONE
INTRODUCTION

The Thyroid Gland
The thyroid gland is located in the anterior neck. It weighs approximately 20g (in
adults) and is composed of left and right lobes and a small connecting branch or isthmus.
The thyroid gland secretes hormones that modulate the functions of other glands in the
body, ultimately influencing growth, development and metabolic parameters. The
thyroid hormones T4 (thyroxine) and T3 (triiodothyronine) are the only ones produced in
the body that require an essential trace element, iodine for active hormone release and
processing. Iodine exists as a trace element in the soil and is incorporated into many
foods (Boron & Boupeap, 2003). The thyroid is comprised of numerous follicles, which
are the functional units of the gland. Each follicle consists of a luminal space, filled with
colloid and enclosed by a single layer of follicular epithelial cells. The colloid is a highly
proteinaceous material comprised mainly of thyroglobulin. T4 and T3 are part of the
primary structure of thyroglobulin (Boron & Boupeap, 2003; Boorman et ah, 1990).
Thus the hormones, produced by the thyroid gland, are stored in the luminal space as part
of the thyroglobulin molecule.
The thyroid gland is predominantly regulated by the hypothalamus and the
anterior pituitary gland. These glands release thyrotropin-releasing factor (TRH) and
thyroid stimulating hormone (TSH) respectively. TRH stimulates the synthesis and
secretion of TSH which then functions to stimulate the synthesis and release of T4 and T3
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into the blood. However, TRH and TSH are controlled by the levels of circulating
thyroid hormones that exert a negative feedback control over their secretion (Boron &
Boupeap, 2003). TSH also stimulates the uptake of iodine in its anionic state into the
gland via the follicular cells. It further stimulates the addition of iodine to tyrosine
residues of thyroglobulin stored in the follicular lumen.
Iodine enters the body as iodide anion (I"), which is rapidly absorbed by the
thyroid gland and is then actively taken up by the follicular cells via the Na/I
cotransporter also know as the Na Iodide Symporter (NIS). This NIS is located on the
basolateral membrane of the follicular cell and its activity is increased by TSH. T is then
released from the follicular cells into the lumen of the follicle.
Unlike other peptide hormones, the thyroid hormones (which are amines) do not
bind to specific membrane receptors. Instead, like steroid hormones, they bind to nuclear
receptors. Subsequently, these nuclear receptors bind to thyroid response elements in
promoter regions specific for genes regulated by thyroid hormones e.g. genes that encode
Sodium-Potassium (Na-K) pump, gluconeogenic enzymes, respiratory enzymes, myosin
heavy chain, |3 adrenergic receptors and many others (Boron & Boupeap, 2003).
Biologically, T3 is more potent and thus important than T4. Most of the T4 is converted to
T3 in target cells. Also, the thyroid hormone receptors (THR) have a greater affinity for
T3 than for T4 (Boron & Boupeap, 2003).
Many disease conditions arise when thyroid function is deregulated:
Hypothyroidism, Hyperthyroidism, Sick Euthyroid Syndrome, Cretinism (congenital),
Hasimoto’s thyroiditis, Graves Disease (autoimmune) and others (Boron & Boupeap,
2003). The thyroid gland is important in maintaining many biological processes of the
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human body. Thus, it is important to study factors that influence the functioning of this
gland so that a better understanding of thyroid disease processes can be elucidated.
Based on this, steps can be taken to develop treatment strategies in an attempt to
eliminate diseases which arise when the thyroid function is altered.

The Effects of Radiation on the Thyroid Gland
Thyroid cells are stationary in the cell cycle and, in an adult human, they have a mitotic
index of about 1-3/1000 cells (Clifton, 1986). The thyroid is very susceptible to the
effects of chemical imbalances that alter organification and functional processing.
However, because of their low cell turnover rate they are protected from the immediate
expression of effects linked to radiation exposure. The length of time taken for radiationinduced thyroid tumors to be manifested varies depending on the dose and type of
radiation exposure (protons, neutrons, or X-ray).
Since the Chernobyl nuclear reactor accident in 1986, reports have shown that the
incidence of thyroid disease has increased which demonstrates the radio-sensitivity of the
thyroid gland, especially in children. Carcinoma of the thyroid gland was the principal
disorder detected in children living in fallout regions surrounding Chernobyl (Nikiforov
et al. 1995; Drozd e/a/. 1995). Drozd et al. reported that males and females developed
carcinoma equally during this time. However, as expected, females were more likely to
develop other types of thyroid disorders (autoimmune thyroiditis, nodular and colloid
goiters) (Droid et al. 1995). The radiation effects on the thyroid gland caused by the
Chernobyl accident, resulted mainly from exposure to the radionuclide, iodine, which
becomes concentrated in the thyroid as a result of external exposure &/or ingestion
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(Nikiforov et al. 1995). It is not entirely clear as to why adults, living near, or employed
to cleanup Chernobyl, failed to develop thyroid carcinoma after exposure (Inskip et al.
1995). Two reasons have been suggested. First, not enough time has elapsed for cancer
to show up in the adult thyroid. This seems to be plausible due to the fact that there are
many reports of thyroid cancer developing in people who were exposed in previous
decades. Examples include the Israel tinea capitis x-ray exposure cohort (Lubin et al.
1995; Ron et al. 1989), exposures from radioiodine therapy (Henze et al. 1998; Granter
& Cibas, 1997) and radiation treatment for other cancers (such as head and neck cancer)
(Grobhnol et al. 1997; Leung & Guiney, 1996). Most of these studies revealed that the
latency period before the development of thyroid cancer, in adults, appears to be
approximately 20 years. Second, there is a difference in the growth rate of the thyroid in
adults versus children. Two conditions are assumed necessary for thyroid cancer
development (Williams, 1994): 1) a mutagenic event (radioactive fallout), and 2) growth
promotion, which occurs more rapidly in children (latency period for children postChernobyl was 4 years) (Nikiforov et al. 1995).
Recently, it has been shown that thyroid cancer (not breast cancer) is the fastest
growing cancer in American women. Also, it is now the fastest growing type of fatal
cancer among men (Smith, 2005). Women are reported to be more likely to develop
thyroid cancer than men and it normally occurs in persons between 30-50 years. The
reason for this sudden rise in the incidence of thyroid cancer is not clear. Iodine
deficiency and genetic factors are believed to play a role. Studies have also shown that
adults, who received radiation treatment as children for conditions, such as acne and
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swollen tonsils or adenoids, are at greater risk of developing thyroid cancer (specifically
papillary cancer) (Smith, 2005).
There are four known types of thyroid cancer: papillary, follicular, anaplastic and
medullary thyroid cancer. Papillary cancer is the most common type of thyroid cancer,
occurring in 80-85 percent of all cases. It most often develops as a result of radiation
exposure and it is highly likely to be cured (Smith, 2005). The second most common
type of cancer is follicular cancer which occurs in 5 to 10 percent of all cases.
Individuals from countries wherein the iodine intake is low are at greater risk of
developing this type of thyroid cancer and it is also highly curable (Smith, 2005).
Anaplastic carcinoma is very uncommon and only occurs in 5 percent of all thyroid
cancers. It is a very aggressive type of cancer with a high fatality rate and is believed to
occur as a result of a pre-existing case of papillary or follicular cancer (Smith, 2005).
Medullary thyroid cancer also occurs in 5 percent of all thyroid cases and involves the C
cells of the thyroid gland. This type of cancer is also aggressive and it metastasizes to
other parts of the body before a lump is detected in the thyroid (Smith, 2005).
Taken together, the findings in the literature indicate that radiation affects the
thyroid leading to the onset of certain diseases e.g. thyroid cancer. We believe that TGFpi plays a role in these radiation-induced effects. Therefore, we studied the effect of
radiation on our thyroid cell line, FRTL-5.

The General Properties and Functioning of TGF-pl
Transforming Growth Factor-beta 1 (TGF-pi) is a member of the TGF-P
superfamily which also includes bone morphogenic proteins (BMPs), growth
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differentiation factors (GDFs), miillerian inhibiting substance (MIS), activins and others
(Figure 1) (Feng & Derynck, 2005; Massague et ah, 2005; Gomperts et ah, 2003). There
are at least five existing isoforms of TGF-|3 three of which are mammalian isoforms and
the most commonly studied (TGF-(31, 2 and 3) (Quirin et ah, 1996; Clark& Coker, 1998).
These TGF-(3 isoforms are highly conserved among species and they interact with
varying receptor components (Massague et ah, 1992; Clark& Coker, 1998) (Figure 1). In
our study we focused on the role of TGF-pi in regulating the cellular properties of
FRTL-5 cells.
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TGF-P superfamily

BMP2
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(Dpp)
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BMPS
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BMP4

GDF5
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TGF-pS

GDF3/
VG32
TGF-32

Activin 3A

Activin PB

Activin pC

Activin PD

Figure 1. The TGF-J3 family tree. TGF- (31 superfamily is comprised of many
subfamilies and members. The members represented are those which are identified so far
in humans and/or mouse, Drosophila melanogaster, Caenorhabditis elegans and Xenopus
laevis.

It has been established that TGF-(31 is a versatile molecule with diverse functions
including proliferation, cell growth inhibition and others (Table 1). The function of this
secreted cytokine is dependent on the tissue type and whether the tissue is normal or
transformed at the time of receipt and response to TGF-(31.
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Table 1. The General functions of TGF-(31
General Functions of TGF-pi

References

cell proliferation

(Barcellos-Hoff et al., 1994; Feinberg et
al., 2004.; Lutz & Knaus, 2002;
Yamamura et al., 2000; Yue et al., 2004;
Zhao &Young, 1996)

cell growth inhibition

(Feinberg et al., 2004; Ohnish et al.,
2004; Yue et al., 2004; Zhao &Young,
1996)

differentiation

(Feinberg et al., 2004; Gerdes et al,
2004; Lutz & Knaus, 2002; Yamamura
et al., 2000; 1990; Mammas et al., 2004;
Zhao &Young, 1996)

extracellular matrix formation

(Feinberg et al., 2004; Gooch et al.,
2004; Roberts et al., 2001; Yue et al.,
2004; Zhao &Young, 1996)

immune modulation

(Feinberg et al., 2004)

modulation of wound healing and
fibrinogenesis

(Ikejima et al., 2004; Roberts et al.,
2001; Shultze-Mosgau et al., 2003;
Seong et al., 2000)

migration

(Lutz & Knaus, 2002; Yue et al., 2004)

apoptosis

(Lutz & Knaus, 2002; Yamamura et al.,
2000; 1990; Yue et al., 2004)

Other molecules produced by tissues present in the extracellular matrix (ECM)
may serve to either up-regulate or down-regulate the production of TGF-|31 and/or its
receptors, thus triggering its autocrine inhibition of growth and differentiation or its
opposite function in growth promotion and tumor development. TGF-f31 can act in an
autocrine and/or paracrine fashion (Smith et ah, 1996; Letterio & Roberts, 1998; Lazar-
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Molnar et al., 2000). These autocrine and paracrine actions of TGF-pi are correlated to
its primary dual role as a growth inhibitor or a growth promoter depending on the cell and
tissue type or depending on whether the cell is normal or malignant. In our study we
focused on this primary dual function and how radiation and repeated sub-culturing
affected TGF-(3rs role as a growth inhibitor (tumor suppressor) or a growth promoter
(tumor promoter) in FRTL-5 cells.
TGF-f31 performs its many and varied functions in its bioactive form. Latent TGF(3 is activated by heat, acid or alkaline treatment, binding to thrombospondin,
deglycosylation, proteolysis, or irradiation (Nunes et al; 1997). Reactive oxygen species,
generated by ionizing radiation, as well as other cellular injuries, are reported to
proficiently activate latent TGF-pi (Fleish et al., 2006; Barcellos-Hoff et al., 1994;
Barcellos-Hoff et al., 1996).

Synthesis, Activation and Degradation of TGF-pl
Like many proteins, TGF-p protein is synthesized and secreted in its latent form
(Barcellos-Hoff et al., 1994; Lutz et al., 2002; Pardali & Moustakas, 2007). Latent TGFpi is made as two pro-peptides which form dimers. Each pro-peptide consists of an Nterminal latency associated peptide (LAP) (65-75kDa) which is non-covalently associated
with a C-terminal mature TGF-P 1 (25kDa) (Figure 2). LAP aids in trafficking TGF-P 1
from the cell into the extracellular matrix and also keeps TGF-P 1 in its biologically
inactive state. The pro-peptide dimer (LAP + TGF-pi) is termed small latent TGF-P
(LTGF-pl). LTGF-pi associates with latency binding protein (LTBP) in the Golgi
apparatus to form large latent TGF-P 1, thus aiding in its rapid secretion and subsequent
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deposition into the ECM (Gleizes et al., 1997; Oklii & Hesketh, 2000) (Figure 2). The
complex remain in the ECM until activation occurs through proteolytic cleavage of LAP
by plasmin/plasminogen, thrombin, plasma transglutaminases, endoglycosylase,
deglycosylation of LAP or interaction with thrombospondin-1 or specific integrins (Lutz
et ah, 2002; Fleish et ah, 2006). LTBP, along with transglutaminase, also functions to
localize LTGF-(31 to the ECM (Figure 2). It is believed that proteases, e.g. plasmin, then
release the complex from the ECM. The proteolytic activity also results in the truncation
of LTBP and thus exposes regions on LAP so that it can bind to the mannose-6phosphate (M6P-R)/IGF-II receptor (Figure 2). Here, a second proteolytic cleavage
occurs which releases the active TGF-pi dimer so that it can bind to its receptors and
enable the signal transduction pathway (Gleizes et ah, 1997) (Figure 2). After a time, the
plasmin levels are reduced by plasminogen activator inhibitor (PAI), which will in turn
decrease the activation of TGF-pi. This action serves to control TGF-pl activation and
subsequent signaling making the activation of L-TGFf31 self limiting and not continuous
(Gleizes et ah, 1997).
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Figure 2. Activation of latent TGF-pi. Latent TGF-pi (small latent TGF-P or LTGF-pi)
associates with latency binding protein in the Golgi apparatus (LTBP) to form large latent
TGF-(31, thus aiding in its rapid secretion. LTBP, along with transglutaminase (TGase),
also functions to localize L-TGF-f31 to the ECM. Serine proteases, e.g. plasmin, then
release the complex from the ECM. The proteolytic activity also results in the truncation
of LTBP and thus exposes regions on LAP so that it can bind to the M6P-R/IGF-II
receptor. Elere, a second proteolytic cleavage occurs which releases the active TGF-pi
dimer so that it can bind to its receptors and enable the signal transduction pathway.
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Clark and Coker have reported that TGF-(31 activity may be inhibited when it
binds to matrix, a2-macroglobulin and to decorin. A2-macroglobulin may assist the
action of TGF-pi on cells bearing a2-macroglobulin receptors. Hepatic M6P-R/insulinlike growth factor II receptors bind TGF-pi/a2-macroglobulin complexes so that they are
possibly catabolized. Bioactive TGF-f31 may also be degraded by proteases and
elastases, which are released at sites of inflammation or TGF-|31 might be excreted in the
urine (Clark & Coker, 1998).

Key Players and Events Related to the TGF-pi Signaling Pathway
TGF-pi Signaling via TGF-|3 Receptors Types 1 and 2 and the Role of
Accessory Proteins.
Cellular signaling through TGF-(31 occurs when this activated homodimer binds
to specific serine/threonine kinase receptors, TGF-|3 receptors types 1 and 2 (T(3RI and
TpRII) (Asano et al., 2004; Lutz et ah, 2003; Roberts et ah, 2001; Rodriguez et ah, 1995;
Wrana et ah, 1992; Yue et al., 2004; Fleish et al., 2006). These two receptors are similar
in that they are both glycoproteins, which have molecular weights at 55 and 70 kDa
respectively. Both have a single segment that extends across the membrane and an
intrinsic serine-threonine protein kinase domain in the C-terminal segment (Gomperts et
al., 2003; Massague, 1998) (Figure 3). TpRI differs form TpRII in that TpRI has a highly
conserved region comprised of 30 amino acids, immediately preceding the protein kinase
domain. This region contains the GS (Glycine/Serine) domain with sequence
TTSGSGSGLP. This domain is phosphorylated by the constitutively active TpRII, when
TGF-pi binds, causing TpRI to become activated (Gomperts et al., 2003; Feng and
Derynck, 2005) (Figure 3). The structure of TpRI also contains a binding site for FK 506

13

binding protein (FKBP12), a molecule that may serve to inhibit the signaling function of
the receptor (Figure 3).
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Figure 3. The structure of T|3RI and T(3RII. The TGF-|31 receptors, T(3RI and TpRII, are
serine/threonine protein kinases that posses these kinase domains, cysteine-rich region
and a TGF-f3 binding domain. Tf3RI contains an additional GS domain and a number of
phosphorylation sites. Constitutively, active Tf3RII phosphorylates this domain.
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Other proteins betaglycan (T(3RIII), and/or endoglin and decorin bind TGF-(31,
promoting the storage of TGF-|31, in a biologically inactive form, in the ECM (Gooch et
ah, 2004; Lutz et ah, 2003; Gomperts et ah, 2003; Feng and Derynck, 2005). Betaglycan
and endoglin also enhance TGF-|31 binding to the T|3RII-T(3RI complex by recruiting the
ligand to the membrane receptors (Koli et ah, 1997) (Figure 4). Depending on the
cellular environment, betaglycan can act as a dual modulator, either promoting or
inhibiting TGF-(31 signal transduction (Gooch et ah, 2004). These accessory receptors
also aid in TGF-P responsiveness (Gomperts et al., 2003; Feng and Derynck, 2005).
Decorin functions in binding TGF-P 1 and also facilitates interactions with collagen,
fibronectin, thrombospondin, the complement component Clq, and epidermal growth
factor receptor EGFR. TGF-pi’s interaction with the protein decorin is believed to
regulate its control over the cell cycle (Shi et al., 2004).
Because TGF-P 1 is a disulphide-linked homodimer, its association with TpRII
and TpRI causes them to associate in pairs, forming hetero-tetrameric receptor complexes
(Figure 4). Studies have shown that TGF-P 1 is capable of binding to TpRII in the
absence of TpRI but not vise versa. However, TGF-P 1 cannot signal in the absence of
TpRI. TpRI is required for TGF-P 1 signaling even though may not be necessary for
ligand binding (Ehrhardt et al., 2002; Feng et al., 1995, Rodriguez et al., 1995; Feng &
Derynck, 2005; Fleish et al., 2006). Therefore, in order for normal signaling to occur,
both receptors need to be present in equimolar amounts (Coppa et al., 1997). In the
formation of the active heterotetrameric receptor complex, the TGF-P 1 ligand dimer first
binds to TpRII, causing a conformational change in TpRII, thus allowing it to be
recognized by TpRI. This promotes the recruitment and phosphorylation of the three
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serine and two threonine residues in the GS domain TpRI resulting in its activation
(Roberts et al., 2001; Gomperts et ah, 2003; Fleish et ah, 2006). Thus, TGF-(31 signaling
is transferred through a phosphorylation cascade, in which autophosphorylated and
constitutively active T(3RII phosphorylates (activates) TpRI (Ohnish et al., 2004; Fleish et
al., 2006) (Figure 4).

Downstream Signaling of TGF-pi via Smads
To continue the signaling network, from the receptor to the nucleus, TGF-pi
signals through Smad proteins. The Smad proteins are usually classified into three
groups on the basis of their structure and functions: receptor regulated Smads (R-Smad,
which consists of Smads2 and 3), common mediator Smad (Co-Smad, Smad4 being the
most common type) and inhibitory Smads (I-Smads e.g. Smad?) (Ohnish et al., 2004;
Gomperts et al., 2003; Fleish et al., 2006).

Structural Domains of the Smads
The Smad proteins possess two regions of homology, MH1 and MH2 (Mad
Homology 1 and 2) at the N- and C-terminals respectively (Figure 5). R-Smads and CoSmads also possess an intermediate linker domain between the MH1 and 2 domains. The
MH1 domain participates in trafficking to the nucleus and in DNA binding and proteinprotein interactions. Smads are regulated via their linker domain by other signaling
kinases (e.g. mitogen activated protein kinases (MAPK) or cyclin-dependent kinases
(CDKs) that phosphorylate the Smads in this region. The half-life of Smads and TpRI are
also regulated in this region by ubiquitin ligases. The MH2 domain also participates in
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protein-protein interactions (Massague et al., 2005; Pardali & Moustakas, 2007). RSmads each possess an SxS phosphorylation site (comprised of serine residues), in the
MH2 domain of the C-terminus (Figure 5). It is at this site that they undergo
phosphorylation by activated T(3RI. The SxS site of Smad2 is comprised of Ser 465 and
Ser 467 while the SxS site of Smad3 is comprised of Ser 423 and Ser 425. R-Smads also
posses an L3 loop in their MH2 domains (Figure 5) which interact with the L45 loop of
T(3RI, thus causing a conformational change in the structure of the R-Smads. This then
allows the R-Smads to bind to Smad4 (Massague et al., 2005; Gomperts et al., 2003).
Unlike the R-Smads, Smad4 lacks the consensus substrate sequence SxS and thus is not
phosphorylated by any of the receptors (Gomperts et al., 2003; Pardali & Moustakas,
2007). Smad7 also lacks the C-terminal SxS phosphorylation site and possesses an MH1
domain which is not homologous to the MH1 domains of the R- and Co-Smads (Figure
5).
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Figure 4. The TGF-J31 signaling pathway. Active TGF-(31 binds to the cell surface
T(3RII/ TpRI hetero-tetrameric receptor complex. TpRII trans-phosphorylates T|3RI.
TPRI then phosphorylates R-Smads, which forms a complex with Co-Smads. The
complex thus moves to the nucleus where it binds to DNA and interacts with
transcriptional co-factors (TF) and co-activators to regulate transcription. Transcriptional
activation of I-Smads and Smurfs are also controlled by these transcriptional factors.
These autocrine inhibitors of the TGF-(31 remain until the appropriate time when they are
exported from the nucleus to the cytoplasm where they form complexes with R-Smads
and with the TGF-pi receptors, resulting in receptor ubiquitination (Ub) and endocytosis
followed by lysosomal degradation. The I-Smad also inhibits R-Smad phosphorylation by
the receptor complex.
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Figure 5. Structure of the Smads. There are three sub-groups of Smads: receptor
regulated Smads (R-Smad), co-operative Smads a (Co-Smads) and inhibitory Smads (ISmads). R-Smads and Co-Smads contain conserved N terminal (MH1) and conserved
(MH2) domains. These domains sandwich a linker region. I-Smad contains only the
conserved MH2 domain.

Smad Activation and Signaling
Upon ligand binding, active T(3RTs phosphorylation of Smad2 and 3, triggers
their activation (Asano et ah, 2004; Deep et ah, 2003; Feinberg et ah, 2004; Lutz et ah,
2003; Ohnish et ah, 2004; Yue et ah, 2004) (Figure 4). This promotes the interaction of
Smad2/3 with Smad4, and the resulting complexes translocate and accumulate in the
nucleus wherein they act as transcription factors (Asano et ah, 2004; Feinberg et ah,
2004; Feng et al., 1995; Lutz et al., 2003; Ohnish et al., 2004; Wrana et ah, 1992;
Gomperts et al., 2003; Pardali & Moustakas, 2007). The Smad complex may bind to
DNA directly at Smad-binding elements (SBE) or they may associate with a number of
transcription factors (e.g. the Jun and Fos family of transcription factors and E2F),
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cofactors (e.g. FoxH, FoxO, and Mixer), adaptor proteins (e.g. MSG1, SMIF) co
activators (e.g. CBP, p300 and P/CAF) and co-repressors (e.g. TGIF and SnoN), thus
leading to transcriptional activation or repression of a wide variety of genes (Pardali &
Moustakas, 2007). By itself, the Smad complex has weak affinity for binding DNA
sequences. However, association with other accessory proteins enhances binding of the
complex (Feng and Derynck, 2005; Massague et ah, 2005). For example, instead of
binding to the AP-1 DNA binding site directly, the Smad complex interacts with the Jun
and Fos family of transcriptional factors along with other accessory proteins to regulate
transcription (Yamamura et al., 2000).

Negative Regulation of the TGF-pl Pathway by the Inhibitory Smad?
I-Smads (e.g. Smad?) and ubiquitin ligases of the Smurfs family play important
roles in down-regulating the TGF-pl signaling pathway. The gene expression of these
Smads and Smurfs (Smurfl and 2) are rapidly induced by the TGF-pl/Smad signaling
pathway (Izzi et al., 2004; Pardali & Moustakas, 2007) (Figure 4). It has been shown that
Smad? and Smurfs are preferentially localized in the nucleus. Smad? contributes to
inhibition of the TGF-pi signal in three main ways. 1) Smad? may leave the nucleus and
bind directly to TpRl, thereby blocking R-Smad access to the receptor and as a result
inhibit R-Smad phosphorylation. 2) Smad? may act as an adaptor protein by forming a
complex with Smurfl or 2 in the nucleus. The complex is then exported from the nucleus
to the cytoplasm where Smad? recruits Smurf to the TGF-pi receptor complex and
activates the catalytic activity of this ubiquitin ligase. Smurf thus binds to the complex
and degrades both Smad? and the receptor complex via ubiquitination. 3) Smad may
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also recruit phosphatases that dephosphorylate and inactivate the receptor complex (Izzi
et ah, 2004; Pardali & Moustakas, 2007).

TGF-pl’s Dual Role as a Tumor Suppressor and a Tumor Promoter
Because TGF-pi has both growth suppressive and apoptotic effects in many nontransformed epithelial cells and cell lines, it is considered a tumor suppressor during the
first stages of carcinogenesis (Roberts and Wakefield, 2003; Siegel and Massague, 2003).
Studies have shown that mutational events, that render tumor suppressors in the TGF-|31
signaling pathway inactive, may abolish TGF-pi’s function in preventing tumorigenesis
and could result in the onset of various human cancers (Levy & Hill, 2007; Pardali &
Moustakas, 2007). Such pathway players include the TGF-pi receptors, Smads2, 3 and 4
(Garrigue-Antar et al., 1995; Knaus et ah, 1996; Wang et al., 2000; Eppert et ah, 1996;
Yakicier et al., 1999; Maliekal et al., 2003; Prunier et al., 2001; Han et al., 2004, Cerutti
et al, 2003; Pardali & Moustakas, 2007). For example, in head and neck tumors, G-C
transversions either inactivate the TpRII kinase activity, thus preventing this receptor
from activating TpRI or constitutively activate the kinase leading to abnormal signaling
(Garrigue-Antar et al., 1995; Knaus et al., 1996; Pardali & Moustakas, 2007). Oncogenes
such as Myc, Ras, Ski and SnoN also play roles in inactivating the XGF-pi signaling
pathway and thus promote tumorigenesis. Myc, Ski and SnoN act mainly by binding to
Smads, preventing them from acting as transcriptional factors for inducing the expression
of XGF-pi response genes (Figure 6) (Pardali & Moustakas, 2007). Oncogenic mutant,
ras, acts by superactivating Erksl/2 which phosphorylate linker domain of Smads2 and 3,
causing them to remain in the cytoplasm, thus inhibiting their nuclear function (Pardali &
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Moustakas, 2007) (Figure 6). The ubiquitin ligase, Smurf2 can function as an oncogene
by inducing Smad and TGF-p receptor degradation, thus inactivating the pathway.
Another ubiquitin ligase for p53 (MDM2) is also an oncogene which was also found to
confer resistance to the growth inhibitory response of epithelial cells to TGF-|31 (Pardali
& Moustakas, 2007). Smad7 functions as an oncogene when it is overexpressed in
cancers such as malignant thyroid follicular cell carcinomas due to its inhibition of the
TGF-pi pathway (Cerutti et al, 2003; Pardali & Moustakas, 2007). When TGF-f31 acts a
tumor suppressor, it functions to mediate growth regulation, DNA damage responses,
apoptosis, as well as to maintain tissue integrity and chromosomal stability (Glick et al,
1996). However, during the later stages of transformation, TGF-(31 triggers tumor
progression by promoting metastatic carcinomas. As a tumor promoter, it triggers the
epithelial to mesenchymal transition, tumor cell invasiveness and regulation of tumor
angiogenesis (Roberts and Wakefield, 2003; Siegel and Massague, 2003; Pardali &
Moustakas, 2007). TGF-pl does not only stimulate Smad signaling, but it also triggers
MAPK, Rho-GTPase, Erkl/2, PI3K, NF-kB and p38 signaling when it functions as a
growth promoter (Pardali & Moustakas, 2007).

TGF-pi’s Role as a Tumor Suppressor in Cell Cycle Regulation
and in Cellular Senescence

TGF-pi’s Regulation of Cell Cycle and Cell Growth
TGF-pl exerts control over cell cycle progression, specifically at the Gl-S
transition. Other important players in cell cycle progression are categorized into two
protein families: the cyclins and the CDKs. Activation of cyclin D/CDK4 (or) 6 and

23

cyclin E/CDK2 complexes promote transitions from early to late G1 phases and from late
G1 to S phases respectively (Yue & Mulder, 2001). One of the ways in which they
achieve this is by inducing cyclin A production via Retinoblastoma (Rb) phosphorylation
or by associating with pi07 and pi30 (Rb like proteins) (Feng et ah, 1995, Boyer et ah,
2005, Gomperts et ah, 2003). These interactions prevent the Rb proteins from
associating with the E2F transcription factor. This allows E2F to interact with the
transcription response elements (TREs) in the cyclin A promoter sequence and thus
induces cyclin A transcription (Feng et ah, 1995; Boyer et ah, 2005; Gomperts et ah,
2003). E2F is also known to regulate the expressions of other S and G2 phase cyclins
such as cyclins B and E (Boyer et ah, 2005). Once cyclin A is produced it can interact
with Rb, pi07, pi30 and the E2F transcription factor. These interactions also promote
Rb hyperphosporylation and therefore aid in cell cycle progression during S phase. (Feng
et ah, 1995).
In most epithelial cell lines, TGF-pl promotes cell cycle arrest in the Gi phase,
thus preventing Gi to S phase transition (Feng et al., 1995; Boyer et al., 2005). It does so
by activating the transcription of the cyclin-dependent kinase inhibitors (CKIs), pi 5 INK4B
p21 CIP/WAFl and p27KIP1, and by inhibiting the synthesis and activation of cyclins and
CDKs (Figure 6) (Feng et al., 1995; Boyer et al., 2005, Gomperts et al., 2003; Seoane,
2004; Seoanne et al., 2002). Inhibition of CKIs occurs when the Smad-mediated
transcription factors are repressed. (Figure 6) (Pardali & Moustakas, 2007). For example,
the potential oncogene, c-Myc, can bind to Smads2 and 3 and inhibit pi5 INK4B
transcription. Excess c-Myc in the nucleus can also pair with the pi5 INK4B initiator
element-binding protein (Mizl), forming a repressor protein that blocks pi5 INK4B gene
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expression. However, upon activation of the TGF-J31 signaling pathway, the Smad
complex, along with the transcription factor Spl binds to a GC-rich proximal promoter
region of pi 5 INK4B , thus activating the transcription of this gene (Pardali & Moustakas,
•
2007). p21 CIP/WAFl is
regulated in a similar manner via the Smad complex interacting

with Spl which binds to the GC-rich proximal promoter region of p21 CIP/WAFl , thereby
activating its transcription. In this case however, protein kinase Ca (PKCa) and the
regulatory calcium-binding protein S100C/A11 play a role wherein TGF-pi activates
PCKa which phosphorylates the regulatory subunit of S100C/A11. The calcium binding
protein then translocates to the nucleus where it binds to the Spl and recruits it to the
GC-rich p21 CIP/WAFl promoter (Pardali & Moustakas, 2007). The Smad complex is also
involved in the transcriptional regulation of p27K1P1 (Figure 6).
Activated p27 KIPl and p21 CIP/WAFl bind to cyclin/CDKs complexes and inhibit
their activity, particularly the cyclin E/CDK2 and the cyclin D/CDK4 (Figure 6). These
inactivated cyclin/CDK complexes are no longer able to hyperphosporylate Rb or
associate with pi07 and pi30. Hence these Rb-like proteins are free to bind to and
inactivate the E2F transcription factor, thus preventing the expression of other cyclins (or
other players that promote cell cycle progression), particularly cyclin A (Feng et al.,
1995; Boyer et al., 2005; Gomperts et al., 2003) (Figure 6). p27 KIPl and p21 CIP/WAFl also
bind to CDK4 and 6 respectively, inhibiting the phosphorylation and activation of these
CDKs and preventing them from associating with cyclin D. When pi5 INK4B becomes
activated it binds to CDK4 and 6, thus displacing p27KIP1 and p21 CIP/WAFl , and continues
to prevent the CDKs from associating with cyclin D. The displaced CKIs then bind to
CDK2 and block its activity. This hinders CDK2 from binding to cyclins A and E and
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causes the cell to arrest at the G1 to S phase transition (Feng et ah, 1995; Gomperts et ah,
2003; Boyer et ah, 2005; Fleish et ah, 2006; Pardali & Moustakas, 2007).
Additional research has shown that TGF-(31 activates p53, a tumor suppressor
protein which in turn activates p21CIP/WAFl transcription. p53 does this by binding
directly to a distal enhancer element of the p21CIP/WAFl gene or by interacting directly
with the Smad complex, thus stabilizing the transcriptional complex and providing
enhanced induction of its expression. This then promotes cell cycle arrest (Ewan et ah,
2002b; Pardali & Moustakas, 2007).
TGF-pi may also promote cell cycle arrest by inhibiting the members of the Id
family (Idl-3), growth promoting transcription factors (Chen et ah, 2002; Kang et ah,
2003; Kowanetz et ah, 2004; Pardali & Moustakas, 2007). Transcriptional repression of
all three family members occurs via Smad signaling. The Idl gene is repressed when
Smad complexes interact with the ATF3 transcriptional factor while Smad, along with
Mad2 and 4 (antagonists of c-Myc), repress Id2 gene expression. It has been shown that
down-regulation of endogenous epithelial Id2 and 3 by TGF-f31 is absolutely necessary
for cell cycle arrest to occur. This is because Id antagonizes the anti-proliferative effects
of p21CIP/WAFl. Therefore repression of these Ids is necessary for induced expression
of p21CIP/WAF1.
The above information therefore illustrates that the TGF-pl signaling pathway is
unquestionably necessary for cell cycle arrest and that many proteins (tumor suppressors
and proto-oncogenes) are involved in regulating this physiological occurrence.
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Figure 6. TGF-pi’s regulation of cell cycle progression. The TGF-p receptor activates
Smad signaling which in turn function to induce transcription of down-stream genes
involved in cell cycle arrest such as p2iCIP/WAF1 ,p27 KIPl , and pl5INK4B. TGF-pi signaling
via Smads also represses transcription of c-Myc and Id. These genes act by repressing the
transcription of p2lCIP/WAF1 and pl5INK4B . Thus Smad -mediated downregulation of c•
Myc and Id is required prior to p21 CIP/WAF1 and pi 5 INK4B induction.
Ski, SnoN, Smurf and
Ras directly interact with or post-translationally modify the Smad complex thus
repressing its transcriptional activity. The CKIs directly affect the function of
cyclin/CDK complexes, leading to cell cycle arrest at the early G1 phase. The CKIs also
function to promote Rb hypophosphorylation. Hypophosphorylated Rb then binds to E2F
and inactivates this transcription factor so that the transcription of CDKs and cyclins
(such as cyclin A) are inhibited.
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TGF-pl’s Role in Cellular Senescence and Malignant Conversion
Senescence is a physiological response of all cell types in an attempt to resist the
onset of malignancy which is normally linked to the initiation of genomic instability
(Pardali & Moustakas, 2007). Many of the studies on in vitro ageing (also referred to as
replicative senescence or cellular senescence) have been preformed in human diploid
fibroblasts (HDF) (Frippiat et ah, 2002; Toussaint et ah, 2002; Vijayachandra et ah,
2003). Toussaint et al. reviewed the work of Hayflick and Moorhead reported:

HDF divide finite number of times. Three phases of cell division were then
coined: phase 1 represented the primary culture, phase II represented the many
cumulate population doublings (CPDs) of luxuriant growth after the primary
culture, and phase III was termed ‘the Hayflic limit’ (now referred to widely as
replicative senescence). The term ‘Hayflick limit’ refers to senescence of
proliferative cell types in vitro (Toussaint et al., 2002). It has been argued that in
vitro replicative senescence is somewhat different from in vivo senescence since
the gene expression patterns relating to ageing are different. (Quoted by
Toussaint O. et al., 2002).
The major biomarkers of in vitro ageing are: enlarged cell size, senescence
associated {3-galactosidase (SA p-gal) activity, deletions in the mitochondrial DNA, low
c-fos proto-oncogene, decreased induction of heat shock proteins and increased
metalloproteinase activity degrading the ECM. Many reports argue that these biomarkers
are also observed during in vivo aging. In fact, they argue that these biomarkers also
appear after exposure to sub-cytotoxic oxidative stress and DNA damaging agents
(Toussaint et al., 2002). Thus senescence is defined as irreversible growth arrest in
proliferative cell types triggered by telomere shortening and other damaging agents
(Serrano & Blasco, 2001; Wright & Shay, 2001; Toussaint et al., 2002). Stress-induced
senescence-like phenotype or stress-induced premature senescence (SIPS) refers to
proliferative cell types that undergo irreversible growth arrest due to damaging agents
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(Brack et al., 2000; Toussaint et al., 2000; Toussaint et al., 2002). Senescence can
therefore be categorized into two major groups: telomere-dependent senescence and
SIPS. Different forms of senescence may represent barriers against immortalization as
long as irreversible growth arrest is observed. However, according to Toussaint et al.,
telomere-dependent senescence is the ultimate barrier against cell immortalization
(Toussaint et al., 2002).
Tumor suppressor genes primarily function to prevent the onset of
genomic instability which may lead to malignancy (Campisi, 2003; Toussaint et al.,
2002; Vijayachandra et al., 2003; Pardali & Moustakas, 2007). They act in this capacity
by repairing oncogenic damage, e.g. DNA mutations, or by triggering cellular processes
such as DNA repair, apoptosis or cellular senescence that prevent continued proliferation
of potential cancer cells (Campisi, 2003; Pardali & Moustakas, 2007).
TGF-pi and some downstream effectors in its signaling pathway (e.g.
TpRII, Smads2, 3 and 4) are tumor suppressors that prevent tumor cell immortalization,
leading to cancer. They accomplish this by ensuring stability of the genome and by
subsequently regulating the physiological processes mentioned previously. (Pardali &
Moustakas, 2007). In vitro aging, which occurs in response to genomic instability, is
promoted by TGF-pi and its down-stream players (Vijayachandra et al., 2003).
Vijayachandra et al. reported that one of the ways in which TGF-pi regulates senescence
is via Smad3. Smad3 was found to induce pi5 INK4B in part by down-regulating c-myc
which led to keratinocyte senescence. They also discovered that alterations in TGF-pi
signaling resulted in reduced senescence in vitro (in v-ras transduced Smad3 null
keratinocytes) and promoted malignant conversion leading to malignant progression in
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vivo, when grafted into mice (Vijayachandra et ah, 2003). They therefore concluded that
TGF-pi, acting via its downstream effector Smad3, aided in triggering the onset of in
vitro cellular senescence and that the TGF-|31 signaling pathway might not be the only
one involved in triggering senescence via pi 5 INK4B . It is possible that this CKI may be
regulated either by TGF-pl/Smad independent pathways. (Vijayachandra et al., 2003).
Even though there are a number of studies that indicate how TGF-f31
mediates cell cycle arrest and cellular senescence, not many studies exist that illustrate
how this cytokine mediates tumor cell immortalization (Pardali & Moustakas, 2007).
When TGF-pi is deregulated it may no longer serve to promote senescence and as a
result, normal cells may become potential cancer cells (Fleish et al., 2006). Loss of
function mutations introduced into the gene sequences of downstream players of the
TGF-pi signaling pathway result in a higher risk of genomic instability, which leads to
aneuoploidy and cancer progression. This occurs both in vitro and in vivo (Pardali &
Moustakas, 2007). Another way in which TGF-pi promotes senescence is by repressing
the expression of the catalytic subunit of telomerase (TERT). Smad3 interacts with
Menin, another tumor suppressor protein which aids this Smad in binding to DNA and
thus inhibiting TERT expression (Pardali & Moustakas, 2007). On the other hand, TERT
may function to repress TGF-pi regulated genes. It does this via Smad-interacting
protein 1(SIP1) which interacts with Smad3 and recruits co-repressors resulting in
transcriptional repression of these genes. Studies conducted in mammary epithelial cells
have shown that the abnormal expression of TERT, blocks TGF-pi’s growth inhibitory
effect. As a result these cells become tumorigenic and lose their ability to undergo
senescence (Pardali & Moustakas, 2007). Therefore, the repression or expression of
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TERT is important in determining whether tumor cells undergo senescence or whether
they become immortalized.

TGF-P and Radiation
There is evidence to suggest that radiation can selectively regulate TGF(31 isoform expression in rat mesangial cells (O’Malley et ah, 1999). Alteration in
mRNA expression of TGF-P 1 and TGF-p3 occurs very early after radiation exposure.
From these experiments it was suggested that both isoforms contribute to fibrinogenesis
of irradiated liver wherein, TGF-p 1 and TGF-P3 are acting as positive and negative
regulators respectively (Seong et al., 2000). Studies have shown that transcriptional
regulation is involved in radiation-induced activation of TGF-P 1 gene expression in that,
gamma radiation induces nuclear protein binding activity that involves AP-1 sequences
(Gault et al., 2002).
Radiation also regulates TGF-P 1 expression at the protein level.
Experiments have shown that the levels of TGFpi are increased following gamma, X ray
and low energy laser irradiation (Barcellos-Hoff, 2001; Barcellos-Hoff et al., 1994; Green
et al., 2002; Kim et al., 2002; Yin et al., 1999). Data from immunohistochemical
differential antibody staining showed radiation exposure resulted in the activation of
TGF-131 (Barcellos-Hoff et al., 1994; Kim et al., 2002). Latent TGF-131 is predominant in
non-irradiated tissues while the distribution of active TGF-P 1 is restricted. However, as
early as one hour post irradiation, active TGF-p 1 was increased significantly with a
concomitant decrease in latent TGF-P 1 immunoreactivity. This phenomenon persisted
for up to three days and was also observed after exposure to low doses (0.1 Gy) of
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colbalt-60 gamma radiation (Barcellos-Hoff et al., 1994, Ehrhardt et aL, 1997). The
reason for the increase in TGF-pl subsequent to irradiation is due to the fact that TGF-pi
mediates many radiation induced events that control tissue repair, growth and
extracellular matrix production (Barcellos-Hoff, 1993).
TGF-pi induction and its anti-inflammatory effects subsequent to low-dose
radiation are believed to be dose dependent up to a maximum of 0.5 Gy of colbalt-60
gamma ray exposure in endothelial cells (Kamprad et al., 2002). The anti-inflammatory
effects observed as a result of TGF-|31 induction after low-dose radiation includes a
down-regulation of leukocyte/peripheral blood mononuclear cell adhesion (Roedell et al,
2002). Even though O’Malley et al., observed this dose-dependency up to 5 Gy colbalt60 gamma ray exposure in mammary epithelium (Davis et al., 1986; O’Malley et al,
1999), it was not evident in experiments, done by Gridley et al, wherein, C57 BL/6 mice
were whole body gamma irradiated (Gridley et al., 2001). Experiments with C57 BL/6
mice revealed that plasma levels of TGF-|31 were elevated to the same level following
radiation exposures of either 1 cGy/min. or 80 cGy/min. rate of cobalt-60 gamma
irradiation to cumulative doses of 0.5, 1.5 and 3.0 Gy. These experiments inferred that
the plasma levels of TGF-f31 were not affected by the dose or the dose rate of gamma
radiation (Gridley et al., 2001; Kajioka et al., 2000). However, protons did not result in
the same level of induction in irradiated mice (Gridley et al., 2001). We have also found
that the production of TGF-|31 was not dose dependent following colbalt-60 gamma
irradiation in the FRTL-5 cells in vitro (Figure 15).
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Hypothesis and Significance of this Study
Intent on studying the effect of radiation on normal epithelial cells/tissue led us to
utilize the FRTL-5 cell line that, in tissue culture, self-assembles into follicles, expresses
thyroid stimulating hormone (TSH) receptors, and is dependent on TSH for growth
(Ambesi-Impiombato et ah, 1980). In previous studies, the response of the relatively
normal, early passage cultures of FRTL-5 cells were characterized with respect to their
response to gamma-rays and 250 MeV protons. Those experiments yielded differences in
the relative biological effectiveness (RBE) of photons (60Co-gamma) versus protons, with
protons having values of 1.2 to 1.7 for the various endpoints measured (Green et ah,
2001a). Further investigation revealed differences in the properties of the FRTL-5
cultures with repeated passage. When the cells were sub-cultured more than 15 times
their morphology changed and their growth rate increased relative to the earlier passagenumber cultures. The late passage cultures had an accelerated doubling time such that by
passage 25 it was nearly half that of early passage cultures (25 hours versus 49 hours)
(Green et ah, 2001b). The late passage cultures had an approximate 20% reduction in
follicular content (fraction of cells assembled into spherical shells versus monolayers)
and corresponding reduction in thyroxin release.
Investigating reasons for the difference in the cellular properties as a result of sub
culturing revealed that the late passage cells developed a spontaneous mutation in the
only gap junction protein they express, connexin32 (Cx32). The mutation, a point
deletion in the cytoplasmic loop region at nucleotide 378 corresponded to the middle
position of the codon for amino acid 116. The deletion caused a frame-shift converting
the histidine at amino acid 116 to a proline. Four amino acids past the deletion, a
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premature stop codon resulted in truncation of the remaining 60% of the protein and
hence non-functional gap junctions in the late passage cells (Green et ah, 2001b).
Utilizing this naturally occurring mutation allowed the contribution of Cx32 to the
contact effect to be assessed following gamma and proton irradiation. The findings
indicated that the presence of Cx32 gap junction channels conveyed resistance only in
response to gamma radiation (60Co-gamma) (Green et ah, 2002). Our ongoing studies
with FRTL-5 cells led us to discover that these cells display transformed properties with
repeated sub-culturing and that the mutation in Cx32 was not the only possible modulator
of these changes. Growth in normal epithelium is regulated, in part, by TGF-|31. Thus, it
was our intention to investigate whether there were differences in early (sub-cultured 515 times) and late (sub-cultured 16-25 times) passage cultures with respect to their
production of TGF-pi. Clearly, if TGF-|3 is mediating these changes in cellular properties
then the signal transduction mechanism(s) and/or the complement of accessory proteins
must also have changed from those conferring constrained growth toward those leading
to growth promotion. We therefore hypothesized that radiation exposure induced
alterations in the TGF-|31 signaling pathway which contributed to accelerating the
onset of changes in the cellular properties of FRTL-5 cells, similar to those observed
as a result of repeated sub-culturing.
Our goal was to examine the role of TGF-pi production, recognition and
response, to determine whether it contributed to the changes observed in this cell line as a
function of repeated sub-culturing or by the acceleration of these processes following
radiation. We designed three specific aims to aid us in testing our hypothesis: 1. To
document and quantify changes in 1) the levels of TGF-pi, 2) cellular growth rate and 3)
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TGF-P receptor levels between irradiated (2 Gy gamma-rays) and non-irradiated early
and late passage FRTL-5 cultures; 2. To examine whether radiation exposure or
repeated sub-culturing induced changes in the steady-state and phosphorylation levels of
Smad proteins, major downstream players in the TGF-p 1 signaling pathway; and 3. To
determine whether the role to TGF-p 1 in regulating the transcriptional activation of
cyclin A and PAI-1 was altered due to radiation and repeated sub-culturing.
We believed our investigations would aid us in determining whether TGF-P 1 and its
signaling pathway were contributing to the altered cellular properties we observed in
FRTL-5 as a function of radiation exposure and repeated sub-culturing.
Even though extensive research has been performed to elucidate the role of TGFpi in controlling cell proliferation, very few studies have been conducted to investigate
its activity in thyroid cells as they are repeatedly sub-cultured plus/minus radiation
exposure. We believe that it is important to understand how this protein contributes to
promoting the changes observed in our relatively normal thyroid cells as a result of these
factors. By systematically addressing each aspect of this study, we obtained a clearer
understanding of how radiation and repeated sub-culturing affected our cell line and we
were able to investigate whether TGF-p 1 was contributing to these processes. We hope
to use the results we obtained, using our in vitro model, to increase our understanding of
how TGF-p 1 may function in vivo in response to irradiation. This may aid us in
understanding the mechanisms by which radiation exposure triggers the incidence of
thyroid related diseases such as papillary cancer.
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CHAPTER TWO
MATERIALS AND METHODS

Cell Culture
FRTL-5 cells were purchased from the ATCC (Manassas, VA)
(Ambesi-Impiombato et ah, 1980). Upon receipt, the cells were growth expanded and
samples were stored frozen in liquid nitrogen. The cells used in these experiments were
derived from our passage 7 (P7) FRTL-5 stocks. The method of properly culturing these
cells has been previously described (Ambesi-Impiombato et ah, 1980; Green et ah,
2002a; Green et ah, 2001). P7 FRTL-5 cells were retrieved from liquid nitrogen and
plated in 4 T-75 cm2 flasks. The cells were cultured in DMEM/F12 medium
supplemented with 5% calf serum (Summit Biotechnologies, Fort Collins, CO), lOng/ml
somatostatin, lOng/ml glycyl-L- lysine acetate, 5pg/ml transferring, lOnM
hydrocortisone, 1 X 10‘3 U of TSH and lOpg/ml insulin (Sigma Chemical Co., St. Louis,
MO). The cultures were allowed to establish into adherent follicular cultures for 5 days
with medium changes when necessary. On day 5, two of the flasks were irradiated with 2
Gy colbalt-60 gamma rays and two flasks served as the un-irradiated controls. Fortyeight hours post irradiation the supernatants were removed, and aliquots stored frozen (70°C). The cells were lifted from the flasks by trypsinization and were used for re
seeding 2 flasks to continue the process with a fraction of the remaining cells used to
plate a 96-well plate for assessment of growth rate and a 6-well plate (with cover-slips)
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for immuno-labeling of TGF-J3 receptors (TpRI and T|3RII). The rest of the cells were
frozen in liquid nitrogen for future tests. This process was repeated eleven times with
supernatant, growth rate, immuno-labeling and frozen samples acquired at each level of
sub-culture.

Source of Radiation
To allow us a standard frame of reference, we selected a dose rate and dose (2
Gy) similar to that used in the clinical setting for the characterization of these thyroid
follicular cultures and TGF-(3 production. An upgraded El Dorado cobalt-60 unit was
used to supply the gamma rays for these studies. The beam was directed vertically
downward to project a 30 x 30 cm field at isocenter 80 cm from the source. The dose rate
was approximately 0.7 Gy/minute (Green et al rad. res. 2001).

Cell Proliferation and Growth Rate
The growth rate of FRTL-5 cells was determined using the CellTitre 96 AO
aqueous one solution proliferation assay from Promega (Madison, WI). This assay was
used to determine the growth rate of viable cells by their ability to bio-reduce a novel
tetrazolium compound (3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxy phenyl) -2Htetrazolium, inner salt; MTS) and an electron coupling reagent (phenazine ethosulfate;
PES). The chemical stability of PES is enhanced, which causes it to combine with MTS
to form a stable, colored formazan product soluble in tissue culture medium. Standard
curves were generated from cells of known density (50,000 cells/well, which were two
fold serially diluted) to provide a reference point for the level of dye reduction per cell
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number. Experimental cells were also established in 96-well plates starting at a density
of 5,000 cells/well. The last column in every plate was used for the blank and to test the
medium used to grow the cells. After 48 hrs 20pl MTS was added to all wells and the
plates returned to the incubator for 3 hrs. lOOpl aliquots of supernatant were transferred
in triplicate to clean 96-well plates and read at 490nm wavelength in a Bio-Rad Micro
plate spectrophotometer. The absorbance, at 490nm, of the formazan product was
directly proportional to the number of living cells in the culture. To confirm our results,
we counted the cells by two other methods. First we labeled the cells with propidium
iodide (PI) and obtained cell counts via the Laser Scanning Cytometer (LSC)
(CompuCyte, Cambridge, MA). The properties and functions of the LSC are described
by Green et al. (Green et ah, 2001). Second, we harvested the cells, stained them with
trypan blue and performed manual counts using a hemocytometer.

Enzyme-linked Immunosorbent Assays for TGF-pl
To quantify TGF-(3 (basally active and total) released to FRTL-5 culture
supernatants following radiation we employed a commercially available human TGF-(31
ELISA kit (Quantikine™ kit, R & D Systems, Minneapolis, MN).

The enzyme-linked

immunosorbent assay (ELISA) was used to determine the levels of TGF-f3 in
supernatants collected from the irradiated and non-irradiated FRTL-5 cell cultures. A
portion of the samples was treated with IN HC1 followed by 1.2 N NaOH/O.5 M HEPES
buffer to activate all the latent TGF-J31 present in the sample. The other portion of
samples was left untreated. This assay was a sandwich ELISA that consists of soluble
TpRII, pre-coated onto the assay 96-well microplate. Standards and supernatants were
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pipetted into the respective wells of the microplate. Any TGF-(31 present was bound by
the immobilized receptor. After the microwells were washed to remove the unbound
substances, an enzyme-linked polyclonal antibody specific for TGF-(31 (the antibody was
conjugated to horseradish peroxidase (HRP) was added to the wells in order to sandwich
the already immobilized TGF-pl. The wells were again washed to remove any unbound
conjugated antibody reagent. A substrate, made up of equal portions of stabilized
hydrogen peroxide and tetramethylbenzidine, was added to all wells. The subsequent
enzyme reaction yielded a blue colored solution. The stop solution, which consisted of
6N sulphuric acid, was then added to the microwells which turned the solution color to
yellow. The amount of color (i.e. the absorbance of the solution at the 450nm) was
directly proportional the amount of TGF-pi present in the sample. The concentration of
TGF-pi in each test sample was calculated from the standard curve (obtained by plotting
the ODs (optical density) of the standards against their respective concentrations). The
TGF-pi concentrations measured in the non-treated supernatants represented the
concentration of basally active TGF-pi while the concentration of TGF-pi measured in
the acid-treated supernatants represented the concentration of the total active TGF-pi
contained in the supernatants. Latent TGF-pi concentrations were calculated by
subtracting the basally active TGF-pi from the total TGF-pi concentrations (Latent TGFpi - Total TGF-pi - Basally active TGF-pi).

Fluorescence Immunocytochemistry
FRTL-5 cells, established on cover-slips, were fixed in 70% cold ethanol at -20°C as
previously described (Green et al., 1997). Polyclonal rabbit antisera against TpRI,
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monoclonal mouse antisera against TpRII, the secondary antibodies, Alexa 488conjugated goat anti-rabbit IgG, and Alexa 594-conjugated goat anti-mouse IgG were
purchased from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA) and Molecular Probes
(Eugene, OR) respectively. The cells were counter-stained with 4,6-diamino-2phenylindole-stained (DAPI) (Ipg/ml, Molecular Probes, Eugene, OR) to stain the nuclei
blue. The fluorescent images were quantified using the Laser Scanning Cytometer (LSC)
as previously described (Green et ah, 2001a) and images captured using ImagePro Plus
software via an Oly-750 analog color camera connected to an Olympus BX-60
microscope (Scientific Instruments, Temecula, CA).

Immunoblotting
Immunoblotting for T(3RI and T(3RII
FRTL-5 cells (irradiated and non-irradiated), from various passage numbers, were
cultured to approximately 80% confluency. The protein lysates were then obtained by
scraping in cold immunoprecipitation buffer (IPB; 50mM Tris-HCl pH 7.4, 1% NP-40,
5% Glycerol, 150mM NaCl ImM EDTA, ImM PMSF, 2pg/ml of each protease inhibitor
(Aprotinin, leupeptin and pepstatin), 2mM Na3V04, 2mM NaF and 1% Triton-X),
Iml/lOOmm plate. The protein lysates were incubated on ice for 45mins and then
sonicated for 30 secs. The cell lysates were then centrifuged for lOmins at 12,000 rpm.
Protein concentrations were determined by conducting Bradford assays (Bio-Rad). The
samples were aliquoted and stored at -70°C until ready for use. We ran the appropriate
samples, controls and the SeeBlue Plus2 Pre-Stained Standard (Invitrogen, Carlsbad, CA)
on 10% Bis-Tris SDS PAGE gels (Invitrogen, Carlsbad, CA) for SOmins at 200V. The
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proteins were transferred onto 0.2pm nitrocellulose membranes (Bio-Rad, Philadelphia,
PA). The membranes were stained with Ponseau S, blocked with blocking buffer (5%
non-fat milk, Tris Cl pH=8 (lOmM), 5M NaCl (150mM), Tween 20 (0.05%), deionized
water) and hybridized with 2pl/ml TpRI (mouse monoclonal) or 4p 1/ml RII (rabbit
polyclonal) primary antibody (Santa Cruz Biotechnology, Inc., Santa Cruz, CA) in
blocking buffer for Ihr at room temperature. The blots were then washed and incubated
with 0.25pl/ml rabbit secondary antibody or 0.5pl/ml HRP-goat anti mouse in blocking
buffer for Vi hr at room temperature (Zymed-Invitrogen, Carlsbad, CA). The resulting
blots were then incubated with chemiluminescence substrate (Alpha Innotech, San
Leandro, CA) and subsequently scanned to TIFF files using the Alpha Imager (Alpha
Innotech, San Leandro, CA). To ensure equal loading efficiency, the blots were re
probed with P-actin (mouse monoclonal) primary antibody (Chemicon, Temecula, CA)
and the respective HRP-secondary antibody.

Immunoblotting for Smad Proteins
Irradiated and non-irradiated P8 and PI8 FRTL-5 cells were retrieved from
liquid nitrogen and each cell type was plated into two 100 mm petri dishes. The cells
were cultured to approximately 80% confluency. One of each cell type was treated with
recombinant active TGF-pi (lOng/ml) for 30mins at 37°C and the other was left
untreated. We obtained protein lysates, from these cells and conducted immunoblotting
as described above. Nitrocellulose membranes were stained with Ponseau S, blocked
with blocking buffer and hybridized with the respective primary antibodies: Smad2,
pSmad2, Smad3, pSmadS, Smad4 and MADH7 (Abeam Inc., Cambridge, MA) for Ihr at
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room temperature. The blots were then washed and incubated with HRP- goat anti-rabbit
secondary antibody, HRP-goat anti-mouse and HRP-rabbit anti-goat respectively in
blocking buffer for V2 hr at room temperature. The resulting blots were then incubated
with chemiluminescence substrate (Millipore, Billerica, MA) and subsequently scanned
to TIFF files using the Alpha Imager. To ensure equal loading efficiency, the blots were
re-probed with P-actin (mouse monoclonal) primary antibody and the respective HRPsecondary antibody.

Construction of pGL3-PAI and pGL3-CAL Luciferase Reporter Plasmids
Diagnostic Digest of pCAL2 and p3TP-Lux
The pCAL2 and the p3TP-Lux plasmids have been commonly used to quantity
TGF-pi induced growth inhibition (Feng et al., 1995) and gene expression (Nicolussi et
al., 2003; Wrana et al., 1992). These plasmids were originally constructed by inserting
the respective promoters into the pGL2 basic vector (Promega, Madison, WI) (Feng et
al., 1995; Wrana et al., 1992). We obtained these plasmids as a gift from Dr. Kettering’s
Laboratory, Loma Linda University. In order to ensure that we obtained the correct
plasmids, we performed diagnostic digests wherein we digested both plasmids with Xho I
and EcoRV (Figures 7 and 8). In both plasmids, the inserts contained the Xho I cut site,
while the EcoRV cut site was found in the Luciferase reporter gene. The pCAL2 plasmid
had a size of 6.3 kb so double digest of pCAL with these restriction enzymes produced
two bands at 4.8 kb and 1.5 kb, as was expected, and a single digest with either Xho I or
EcoRV produced the expected 6.3 kb size single band (Figure 7). The un-cut plasmid
was used as a control. The p3TP-Lux plasmid was expected to be 5.8 kb so double digest
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of p3TP-Lux with these restriction enzymes produced two bands at 4.2 kb and 1.5 kb, as
was expected, and a single digest with either Xho I and EcoRV produced the expected
5.8 kb size single band (Figure 8). The un-cut plasmid was used as a control.

PCR (Polymerase Chain Reaction) Amplification of Inserts
In order to reduce background luciferase expression which was high in the pGL2
basic vector, the cyclin A and the PAI-1 promoters were PCR amplified from the pCAL2
and p3TP-Lux plasmids respectively and inserted into the multi-cloning site of the pGL3
basic vector (Promega, Madison, WI). The PAI-1 promoter of 3TP-Lux (3TP) consists of
three tissue-type plasminogen activator (TPA) response elements (TRE) and a portion of
the PAI-1 promoter fused to the adenovirus E4 promoter.

The primer sequences used to

amplify the cyclin A promoter from pCAL2 were:
CGGCGGGGTACCGAGCTCCGTGTTAAATAATTTATGCACATT (forward primer)
and CCCCCCAAGCTTCACTGCTCCCGGGAGTGGACGGCGGG (reverse primer).
The primer sequences used in amplifying the PAI-1 promoter from p3TP-Lux were:
GGACCGAGATCTACATAACCCGGGAGGTACCGAGCT (forward primer) and
GGACCCAAGCTTTTTACCAACAGTACCGGAATGCCAA (reverse primer). The
underlined areas represent restriction sites of Kpnl (forward cyclin A primer), Hindlll
(reverse cyclin A primer), Bglll (forward PAI-1 primer) and Hindlll (reverse PAI-1
primer) respectively. These were included in the primers so that the resulting PCR
amplified promoter inserts contained restriction enzyme cut sites at both ends. A portion
of the PCR reaction was resolved on a 1% agarose gel. Figure 9 illustrates the PCR
inserts of cyclin A (which migrated to 0.761 kb) and PAI-1 (which migrated to 0.391 kb).
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Figure 7. Diagnostic restriction digests of the pCAL2 plasmid. A) The plasmid map of
pCAL2 showing the Xhol and EcoRV restriction sites. B) pCAL2 was digested with two
restriction enzymes, Xhol and EcoRV. Lane 1: Ikb marker, Lane 2: pCAL2 doubly
digested with Xhol and EcoRV, Lane 3: pCAL2 singly digested with Xhol, Lane 4:
pCAL2 singly digested with EcoRV, Lane 5: undigested pCAL2. The digested and
undigested plasmids were resolved on a 1% agarose gel.
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Figure 8. Diagnostic restriction digests of the p3TP-Lux plasmid. A) The plasmid map of
p3TP-Lux showing some of the restriction sites. B) p3TP-Lux was digested with two
restriction enzymes, Xhol and EcoRV (see A)). Lane 1: Ikb marker, Lane 2: p3TP-Lux
doubly digested with Xhol and EcoRV, Lane 3: p3TP-Lux singly digested with Xhol,
Lane 4: p3TP-Lux singly digested with EcoRV, Lane 5: undigested p3TP-Lux. The
digested and undigested plasmids were resolved on a 1% agarose gel.
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Figure 9. PCR amplification of cyclin A and PAI-1 promoter inserts. The promoter
inserts were amplified using the forward and reverse primers constructed for each
promoter. A fraction of the PCR samples was then resolved on a 1% agarose gel. Lane
1: Ikb marker, Lane2: cyclin A, Lane 3: PAI-1. The PCR products contained the
respective restriction sites to facilitate cloning.
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Double Digestion of pGL3-Basic Vector and PCR Amplified Cyclin A
and PAI-1 Promoter Inserts
The PCR products were purified using the QIAquick PCR Purification Kit
according to the specified protocol (Qiagen, Valencia, CA). One microgram of the
purified inserts (cyclin A and the PAI-1 promoters), along with Ipg pGL3-Basic vector
were doubly digested with Kpnl and Hindlll (cyclin A) and Bglll and Hindlll (PAI-1)
respectively in order to create sticky ends which facilitated ligation. The reaction mixture
was digested for 3hr followed by heat inactivation for 15min. The pGL3 digested vector
was then dephosporylated with 0.1 unit/pl Calf Intestinal Alkaline Phosphatase (CIP) for
1 hr to prevent the digested sites from re-ligating. The digested products were resolved
on 1% agarose gels (Figure 10) and their respective gel bands were purified using the
Qiagen DNA Purification Gel Extraction Kit (Qiagen, Valencia, CA).
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Figure 10. Double digest of pGL3-basic vector, cyclin A and PAI-1 promoter inserts.
The cyclin A promoter insert was digested with Kpn I and Hind III while the PAI-1 insert
was digested with Bgl II and Hind III. A portion of each digested products was resolved
on a 1% agarose gel. Lane 1: Ikb marker, Lane2: digested pGL3-basic vector for PAI1, Lane 3: digested pGL3-basic vector for cyclin A, Lane 4: digested PAI-1, Lane 5:
digested cyclin A.

Ligation, Transformation, Propagation and Sequencing of Plasmids
Each digested promoter was ligated with the digested pGL3 basic vector
overnight so that two new plasmids, pGL3-CAL and pGL3-PAI were created. The
plasmid pGL3-CAL contained the cyclin A promoter inserted in Kpn I-Hind III site of
the pGL3-basic vector upstream from the firefly luciferase reporter gene (Figure 11 A)).
The plasmid pGL3-PAI contained the PAI-1 promoter inserted in Bgl II-Hind III site of
the pGL3-basic vector upstream from the firefly luciferase reporter gene (Figure 1 IB)).
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Both plasmids also contained the ampicillin resistance gene (from the pGL3-basic
vector). Each plasmid was then transformed into E coli DH5a. The resulting DH5a
bacterial cells were grown on Luria-Bertani (LB) amp agar plates which selected for the
bacterial colonies that were ampicillin resistant. It was suspected that these bacterial
colonies contained the respective plasmid. Four bacterial colonies, for each plasmid,
were picked and the respective promoters were PCR amplified to determine whether each
colony contained the vector with the insert of interest. As shown in Figure 12, clones 1, 2
and 3 (Lanes 2, 3 and 4) contained the vector with the PAI-1 promoter. Clones 1, 3 and 4
(Lanes 6, 8 and 9) contained the vector with the cyclin A promoter. Four of the same
colonies were picked from each plate and amplified in LB amp broth by vigorously
shaking overnight at 37°C. A portion of each bacterial suspension, containing the
plasmids, was removed and used to make bacterial glycerol stocks, which were stored at 80°C. The remaining bacterial suspensions were then centrifuged and the supernatants
decanted to obtain bacterial pellets, each containing the respective plasmid. The plasmids
were purified by a mini-prep kit (Qiagen, Valencia, CA) and their concentrations
measured using the NanoDrop ND-1000 Spectrophotometer (NanoDrop Technologies,
Wilmington, DE). Two hundred and fifty microliters of each purified plasmid were sent
for sequencing in order to ensure that the promoter sequences were correct and inserted
into the vector with the correct orientation (Davis Sequencing, Davis CA) using RV
primer 3 (Promega, Madison, WI). The resulting sequences were aligned using Clustal
W (Biology Workbench 3.2, San Diego Super Computer Centre, San Diego, CA) and the
plasmid whose sequence matched the known promoter sequence was selected for
subsequent use (see Appendix II, Figures 37 and 38). These selected plasmids were
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amplified and purified by a maxi-prep kit (Qiagen, Valencia, CA) and the plasmid
concentrations were measured using the NanoDrop ND-1000 Spectrophotometer. The
plasmids were then stored at -80°C until prior to use.
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Figure 11. pGL3-CAL and pGL3-PAI plasmid circle map. A) pGL3-CAL contains the
cyclin A promoter inserted into the multi-cloning site upstream form the luciferase (luc+)
reporter gene. A) pGL3-PAI contains the PAI-1 promoter inserted into the multi-cloning
site upstream form the luciferase (luc+) reporter gene. Both plasmids also contain the
Ampr, gene conferring ampicillin resistance in E. coli, fl ori, origin of replication
derived from filamentous phage, ori, origin of replication in E. coli. Arrows indicate the
direction of transcription.
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Figure 12. PCR amplification of PAI-1 and cyclin A insert from DH5a colonies
suspected of containing pGL3-PAI and pGL3-CAL respectively. A portion of four DH5a
colonies, transformed with either pGL3-PAI or pGL3-CAL was added to respective PCR
reaction mixtures in order to determine whether these colonies contained the respective
promoter insert. The colonies with the inserts were amplified and a portion of the PCR
products was resolved on a 1% agarose gel. Lane 1: Ikb marker, Lane 2: PAI-1 clone
#1, Lane 3: PAI-1 clone #2, Lane 4: PAI-1 clone #3, Lane 5: PAI-1 clone #4, Lane 6:
cyclin A clone #1, Lane 7: cyclin A clone #2, Lane 8: cyclin A clone #3, Lane 9: cyclin
A clone #4, Lane 10: lOObp marker.

Transient Transfection Involving pGL3-CAL and pGL3-PAI
Reporter plasmid pGL3-CAL was used to monitor TGF-pi-dependent cyclin A
down-regulation and the pGL3-PAI plasmid to assay TGF-pi-induced PAI-1 induction.
Zero and 2 Gy P8 and PI 8 FRTL-5 cells were seeded in 24 well cell culture plates at 1 x
105 cells/well. Zero and 2 Gy P8 and 18 FRTL-5 cells were grown in 24-well tissue
culture plates to 60-80% confluence. The following plasmids: pGL3-basic empty vector,
pGL3-CAL and pGL3-PAI were co-transfected with pRL-TK. pRL-TK consists of a
renilla luciferase reporter gene placed under the control of the thymidine kinase
constitutive promoter and was used as an internal control to correct for transfection
efficiency. FRTL-5 cells, in each well, were co-transfected with 0.4pg of DNA

55

comprised of the respective test plasmids and empty vector:pRL-TK at a 10:1 ratio.
Transfections were performed using the Effectene reagent (Effectene Transfection
Reagent, Qiagen, Valencia, CA). The Effectene reagent is a unique non-liposomal lipid
formulation designed to achieve high transfection efficiencies. This reagent was used
along with the Enhancer and DNA condensation buffer to promote a high level of DNA
condensation. Effectene-DNA complexes were formed after the effectene reagent was
added to the condensed DNA. Subsequently, the Effectene-DNA complex were mixed
with medium and directly added to cells. The cells were then incubated with the
transfection complexes for 6 hrs. The transfected cells were allowed to recover in media
supplemented with serum and hormones for 24 hrs, after which this media was replaced
with serum-free media containing all the hormone supplements. TGF-J31 (lOng/ml) was
then added to the respective culture wells and the plates were incubated for 24 hrs (for
PAI-1 assay) and 48 hrs (for cyclin A assay) respectively. The cells were lysed in lOOpl
Passive Lysis Buffer (PLB) obtained form Dual Luciferase Reporter 1000 Assay kit
(Promega). The Dual-Luciferase Reporter 1000 Assay System was used according to the
manufacturer’s protocol. Luciferase activities were measured as relative light units
(RLU) in white 96-well microtiter plates (Nunc, Rochester, NY) using a Berthold
Microlumat Plus LB96V luminometer (American Laboratory Trading, Groton, CT).
Twenty microliters of Transfection cell lysate was added to the respective wells. One
hundred microliters of Luciferase Assay reagent (LAR), the substrate for firefly
luciferase was then added to each well (four wells at a time). The luciferase activity was
recorded and subsequently, 100pi StopGlo reagent, which stopped the firefly luciferase
activity and contained the substrate for the renilla luciferase, was added (four wells at a
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time). The Firefly luciferase activity, which reflects the promoter activity of cyclin A or
PAI-1, was normalized to the Renilla luciferase activity to account for transfection
efficiency. The transfection results were represented as Firefly: Renilla ratio (F/R)
obtained by dividing the firefly RLU by the renilla (RLU).

Enzyme-linked Immunosorbent Assay (ELISA) for PAI-1
The Imuclone Rat PAI-1 ELISA kit (American Diagnostica Inc., Stamford, CT)
was used to quantify total rat plasminogen activator inhibitor type 1 (PAI-1) (comprised
of latent, active and inactive PAI-1, as well as tissue-type plasminogen activator (t-PA)
/PAI-1 complexes), produced and released by FRTL-5 cells into culture supernatants
following irradiation and repeated sub-culturing. This assay is a sandwich ELISA that
utilizes a pair of monoclonal antibodies specific for rat P AI-1 reacting with two different
epitopes. Diluted cell lysates and supernatants were added to the respective wells of a
96-well micro plate, previously coated with a mouse monoclonal antibody specific for rat
PAI-1. This was to capture the PAI-1 protein in the solid phase. After the microwells
were washed, the detection antibody conjugate, a second mouse monoclonal antibody
against rat PAI-1 coupled to horseradish peroxidase (HRP), was added to the micro wells.
This antibody bound to the corresponding free epitope on the immobilized rat PAI-1.
The micro well was washed again, after which the peroxidase substrate 3,3 ,5,5 Tetramethylbenzidine (TMB) was added to all wells. The subsequent enzyme reaction
yielded a blue colored solution. Sulphuric acid (stop solution) was then added to the
microwells which turned the solution color to yellow. The amount of color (i.e. the
absorbance of the solution at 450nm) was directly proportional the amount of PAI-1
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present in the sample. The concentration of PAI in each test sample was calculated from
the standard curve which was obtained by plotting the ODs of the standards against their
respective concentrations.

Statistical Analysis
The differences in the levels of TGF-(31 as a function of time and radiation dose
was analyzed by the 1-way Analysis of Variance (ANOVA) test (SPSS statistical
software, Versionl2). The differences in 2 Gy irradiated and un-irradiated cells (P8P18), treated with or without TGF-(31, were also analyzed by ANOVA. Slope analysis of
differences in the rate of cell division between 2 Gy irradiated and un-irradiated cells
were represented by linear regression. Statistical comparisons of the slopes between
irradiated and un-irradiated cells were judged for significance by the Student’s t test
(Sigma Stat, Version 5). “p” values less than 0.05 were considered significant.
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CHAPTER THREE
RESULTS

Evaluation of Changes in FRTL-5 Growth Rate and TGF-pi Ligand Levels After
Radiation and Repeated Sub-culturing
Our ongoing studies with FRTL-5 cells led us to discover that these cells display altered
properties with age (repeated sub-culturing). Some of these properties recorded include
accelerated growth, reduced follicularization and reduction in thyroxin release. We found
that onset of these altered properties were accelerated when cells were exposed to gamma
radiation (60Co-gamma rays) and that the mutation in Cx32 was a possible, but not the
only, modulator of these changes (Green et ah, 2001; Green et ah, 2002). In order to
demonstrate that FRTL-5 cells increase their rate of cell division after radiation and
repeated subculturing, we cultured irradiated and non-irradiated cells from early (P8) to
late (PI 8) passages. The relative rate of cell division increased from P8 to P18 (Figure
13) for both irradiated and non-irradiated cells. As expected, the cells exposed to 2 Gy
divided at a faster rate than the 0 Gy control cells. Significance in the growth pattern was
seen from pass 14 to pass 18 (p < 0.05).
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Figure 13. Relative cell division of 0 Gy and 2 Gy FRTL-5 cells as a function of passage
number. We obtained cell densities in three different ways: MTS assay, PI-LSC and by
manual cell counting using the hemocytometer. The MTS cell counts were normalized
by the PI-LSC and manual cell counts. Relative cell division was determined by dividing
the normalized cell count of the various passages by 0 Gy pass 8. Relative cell division
increased from P8-P18 and radiation exposure accelerated this increase. Significance in
this growth pattern was evident from P14-P18.

Growth in normal epithelium is regulated, in part by TGF-|31. Therefore, we
investigated whether there were differences in early (sub-cultured 5-15 times) and late
(sub-cultured 16-25 times) passage cultures with respect to their production of TGF-pi.
Using a TGF-pi ELISA we measured both basally active TGF-pi and total TGF-
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pi’s activity through acid activation of a sample of the supernatant. The amount of latent
TGF-pi in the supernatant was determined by subtracting the amount of active TGF-pl
(requiring no acid treatment) from total TGF-pi (which contains both active and latent
TGF-pl). The results of those experiments indicated that the late passage cultures were
producing 2.3-fold more total TGF-pi than early passage cultures adjusted for
differences in cell density (p < 0.05) (Figure 14). The basally active and latent forms of
TGF-pi were also significantly higher in the late passages than in the early passages.
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Figure 14. Comparison of early (E) and late (L) passage FRTL-5 cultures with respect to
TGF-pi production. Early and late passages of FRTL-5 cells were cultured in T-75 cm2
tissue culture flasks. The cells were plated at equal density and the cell supernatants were
harvested after 48 hrs and assayed using the TGF-(31 ELISA kit. Separate samples from
each passage were processed. One sample was left un-treated (basally active sample)
and the other sample acid treated to activate the latent TGF-pi in the sample. The acid
activated sample represents the total TGF-|31 in the supernatant as it contains the already
active fraction and the latent form. The TGF-(31 concentrations were recorded as pg/ml.
Results are represented as mean +/- S.D. of triplicate samples of two independent
experiments. TGF-|31 concentration increased significantly between early and late
passages (p < 0.05).
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In the course of conducting our radiation experiments we found that the properties
of the surviving gamma-irradiated early passage cultures resembled late passage cells.
This led us to measure the concentrations of TGF-|31 in the supernatant taken from
irradiated early passage cultures at varying time points following a 3 Gy-gamma radiation
exposure. The result of this time course experiment, using P7 cultures, is illustrated in
Figure 15. These findings showed that the production of TGF-pi due to radiation
increased with time. The radiation-induced production of TGF-pl was also roughly 3fold in this experiment similar to the differences we measured when we compared early
to late passage cells (p < 0.05). Additionally, the levels of TGF-pi increased from the
6hr time point to reach a maximum at 48 hrs after gamma irradiation. It should be
reiterated that the division time for the early passage cells is 48 hrs. Significance in these
time points were observed at 24 hrs compared to 6 hrs and at 48 hrs compared to 6 and 24
hrs (p < 0.05). The concentration then declined at 72 hrs and remained relatively level to
96 hrs. There were, however, significant increases were also evident at 72 and 96 hrs
compared to 24hrs (p< 0.05) (Figure 15). Since we obtained maximum TGF-pi
concentration 48 hrs post irradiation, we used this time point for our subsequent
experiments involving the measurement of TGF-pl levels.
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Figure 15. Production of TGF-pi by early passage FRTL-5 cultures at varying time
points subsequent to a 3 Gy-gamma radiation exposure. P7 FRTL-5 cells were equally
distributed in 6 T-25 cm2 flasks and allowed to grow for 5 days (medium change on day
4) prior to irradiation. Samples of supernatant were removed at the varying time points
indicated (6, 12, 24, 48, 72, 96 hrs) post exposure and assayed by TGF-pl ELISA.
Separate samples from each time point were processed differently, one sample was left
un-treated (basally active sample) and the other sample acid treated to activate the latent
TGF-pi in the sample. The acid activated sample represents the total TGF-pl in the
supernatant as it contains the already active fraction and the latent form. Results are
represented as mean +/- S.D. of triplicate samples of two independent experiments.
Significant increases in the basal and total TGF-pi concentration were evident (p < 0.05).
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Figure 16. Quantifying the levels of TGF-(31 in P7 FRTL-5 cells exposed to varying
doses of gamma-irradiation. FRTL-5 cells (P7) were cultured and subsequently
irradiated with 0.5, 1, 3, 5 and 10 Gy gamma rays the un-irradiated cells (0 Gy) served as
controls. The cells were plated at equal density and the cell supernatants were harvested
after 48 hrs and assayed using the TGF-J31 ELISA kit. Separate samples from each dose
point were processed. One sample was left un-treated (basally active sample) and the
other sample acid treated to activate the latent TGF-(31 in the sample. The acid activated
sample represents the total TGF-pi in the supernatant as it contains the already active
fraction and the latent form. The TGF-f31 concentrations were recorded as pg/ml. Results
are represented as mean +/- S.D. of triplicate samples of two independent experiments.
There was a significant increase in the TGF-pi levels in irradiated compared to nonirradiated supernatants (p < 0.05). Response to radiation appeared to have no dose
dependence (p > 0.05).
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We therefore measured the concentrations of TGF-pl in the supernatant taken
from irradiated early passage cultures following different doses of radiation harvested at
various times post exposure. A representative graph from an experiment using P7
cultures, irradiated with varying doses of Colbalt-60 gamma-rays and harvested at 48 hrs
post-irradiation, is shown in Figure 16. Gamma-radiation induced production of TGF-pi
was roughly 3-fold in this experiment similar to the differences between non-irradiated
early and late passage cells (p < 0.05). Note the response to radiation appeared to have
no dose dependence with the 0.5 Gy response nearly equivalent to the 1, 3, 5 and 10 Gy
doses (p > 0.05).
Additional information regarding the production of TGF-pi by FRTL-5 cultures
under differing radiation conditions were obtained from our microarray analysis of
15,900 rat gene products. Those experiments involved several low doses and included 2
Gy as the high dose with samples harvested at 3 hrs, 2 and 7 days post irradiation. The
microarray information supported the increase of TGF-pi as early as 3 hours post
exposure. This increase was also evident at doses as low as 0.1 Gy (data not shown).
Our data thus demonstrates that as FRTL-5 cells are repeatedly sub-cultured they
display properties consistent with transformation, including; increased production of
TGF-pi, accelerated growth, reduced follicularization with a concomitant reduction in
their release of thyroxin. Irradiated early passage cultures resemble late passage cells
with respect to increased TGF-pl production and growth rate. This suggests that TGF-pi
may be linked to these physical changes resulting in the premature onset of
transformation of early passage cells exposed to radiation. Clearly, if TGF-pi is
mediating these changes in cellular properties then the signal transduction mechanism(s)
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and/or the complement of accessory proteins must also have changed from those
conferring constrained growth toward those leading to growth promotion.

Analysis of TGF-p Receptor Protein Expression
Studies, conducted with our cell line, have shown that FRTL-5 cells, transformed
with v-k-ras oncogene, induce alterations in the TGF-J31 signaling pathway and as a
result, TGF-Pl’s function to inhibit cell proliferation was abolished. Coppa et al.
reported that equimolar amounts of the TGF-P receptors (TpRI and TpRII) were
necessary for normal response to TGF-P 1. It was reported that reduction in TpRII mRNA
and protein levels contributed to an altered signaling pathway in transformed FRTL-5
cells (Coppa et al., 1997). There, however, proved to be no change in the levels of TpRI
(Coppa et al., 1997) although, other reports, in transformed prostate cells, have shown
that alterations in TGF-P 1 signaling may also be due to a reduction in the expression of
TpRI (Kim et al., 1996). Based on this, we believed that the first place to investigate
alterations in the TGF-P 1 signaling pathway, in FRTL-5 cells, was at the level of the
receptors. Thus we measured the levels of TPRI and RII to determine whether there were
differences in their levels and ratios with respect to each other that could contribute to
alterations in the TGF-P 1 signaling pathway. We measured the receptor levels
immunohistochemically (Figure 17) and via western blotting (Figures 18, 19 and 20).
The results shown in Figure 17 revealed that there were no significant differences in the
protein levels or ratios of the TGF-p 1 receptors post-radiation exposure and/or due to
repeated sub-culturing (p > 0.05 ).
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Figure 17. TGF-{3 receptor levels as a function of repeated sub-culturing and radiation.
Immunocytochemistry experiments were performed wherein we used anti-T|3RI (anti
rabbit, 2.5pg/ml) and anti-T{3RII (anti-mouse, 2.5pg/ml) antibodies to identify the
presence and levels of these receptors. The secondary antibodies used were fluorescently
labeled Alexa 488 (5pg/ml) and 594 (5pg/ml) respectively. The slides were analyzed on
the LSC. The ratio of T|3RI to RII was calculated by dividing the average green integral
(Tf3RI) by the average red integral (T|3RII). The results are represented at mean +/- SD of
two independent experiments. There were no significant differences in the protein levels
or ratios of the TGF-|31 receptors post radiation exposure and/or due to repeated sub
culturing (p > 0.05).
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We performed western blots to confirm the results obtained by immunocytochemistry.
We also found that radiation exposure and repeated sub-culture did not contribute to
changes in the levels and ratios of the receptors (p > 0.05) (Figures 18, 19 and 20). We
also conducted 2D gel electrophoresis experiments in later passages (PI5) to determine
whether there was any indication of changes occurring in the migration patterns and
levels of proteins (particularly TpRI and TpRII) as a result of irradiation. Changes in
these patterns would give an indication of whether radiation or repeated passaging
introduced mutational changes that affected protein structure or function. From the result
we determined that there were no differences in the patterns of the visible proteins.
Unfortunately, we did not detect any spot for TpRI, which was supposed migrate at pi 7.2
(first dimension) and 55kDa (second dimension). Also, we did not detect a spot for
TpRII which was suppose to migrate at pi 5.88 (first dimension) and 75kDa (second
dimension) (data not shown). However, since we did not observe any changes where the
other proteins were concerned we did not to pursue protein sequencing experiments.

69

Figure 18. Tj3RI receptor levels as a function of repeated sub-culturing and radiation. A)
Immunoblotting experiments were performed in irradiated and non-irradiated FRTL-5
cells ( P8 andl8). Cell lysates were separated on SDS-PAGE and TpRI was detected
using a rabbit polyclonal antibody to this receptor (upper blot). A mouse monoclonal
antibody to f3-actin was used as an internal control (lower blot). B) The blots were
scanned and the densitometer results were recorded using the Alpha Imager. The results
are represented at mean +/- SE (standard error) of four independent experiments. There
were no significant differences in the Tf3RI receptor levels post-radiation exposure and/or
due to repeated sub-culturing (p > 0.05).
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Figure 19. T(3RII receptor levels as a function of repeated sub-culturing and radiation. A)
Immunoblotting experiments were performed in irradiated and non-irradiated FRTL-5
cells (P8 and 18). Cell lysates were separated on SDS-PAGE and T|3RI was detected
using a monoclonal antibody to this receptor (upper blot). A mouse monoclonal antibody
to P-actin was used as an internal control (lower blot). B) The blots were scanned and the
densitometer results were recorded using the Alpha Imager. The results are represented
at mean +/- SE (standard error) of four independent experiments. There were no
significant differences in the TpRII receptor levels post-radiation exposure and/or due to
repeated sub-culturing (p > 0.05).
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Figure 20. Ratio of TGF-P receptor levels as a function of repeated sub-culturing and
radiation. Immunoblotting experiments were performed with irradiated and nonirradiated FRTL-5 cells (P8 andl8). Cell lysates were separated on SDS-PAGE and both
receptors were detected using the respective antibodies. The blots were scanned and the
densitometer results were recorded using the Alpha Imager. The ratio of Tf3RI to TpRII
was calculated by dividing the corrected integrated densitometer readings (IDV) of TpRI
by those of (TpRII). From these ratios, the relative ratio TpRI to TpRII was calculated by
dividing the ratio of the 2 Gy samples by that of the 0 Gy samples. The results are
represented at mean+/- SE of two independent experiments. There were no significant
differences in the ratio of TpRI to TpRII receptor levels post-radiation exposure and/or
due to repeated sub-culturing (p > 0.05).
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Evaluating the Role of Endogenous and Exogenous TGF-pl on Basal and
Phosphorylated Smad Protein Levels
Given that the TGF-f31 receptors type 1 and 2 were not altered as a result of
radiation and/or repeated sub-culturing, we investigated other players in the signaling
pathway, namely the Smad proteins, to determine whether there were any changes in
their electrophoretic mobility or in their phosphorylated patterns, which would indicate
whether their activity levels were altered. This we believed would aid us in determining
whether the TGF-{31 signaling pathway was functioning normally.
Observations of changes in the levels of basal and phosphorylated Smads 2 and 3
suggest that the normal role of TGF-pi in cell cycle arrest and cellular senescence may
be altered (Pardali & Moustakas, 2007). Smads4 and 7 are also believed to play an
important role in regulating normal signaling as changes in their protein levels point
toward deregulation of the TGF-pl pathway (Pardali & Moustakas, 2007). These
changes have been found to be cell line and tissue specific. We therefore examined the
Smad levels and their phosphorylation patterns (which indicate their activity) subsequent
to the addition of exogenous TGF-pi to determine whether there were changes due to
radiation and repeated sub-culturing.
There were no significant changes in the levels pSmad2 which were induced by
endogenous TGF-pi. In both passages plus/minus irradiation, the addition of exogenous
TGF-pi contributed to a significant increase in Smad2 phosphorylation compared to the
levels triggered by endogenous TGF-pi (p < 0.05). However, there was a decrease in the
exogenous TGF-pi induced pSmad2 levels in irradiated and repeatedly sub-cultured cells
compared to 0 Gy P8 control cells (Figure 21A and B). The decrease in pSmad2 levels
was significant at 0 and 2 Gy PI8 when compared to 0 Gy P8 (p < 0.05). There were no
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significant differences in the inherent un-activated levels of Smad2 for irradiated and
repeatedly passaged cells, regardless of the addition of exogenous TGF-pi.
Endogenous TGF-pi did not induce any significant changes in the levels pSmadB
but there was a significant increase in the levels of pSmadB in 0 and 2 Gy P8 cells after
the addition of exogenous TGF-pi (p < 0.05 (Figure 22A and B). The levels of TGF-piinduced pSmadB decreased significantly in cells that were repeatedly sub-cultured (0 and
2 Gy PI8) compared to 0 Gy P8 control cells (p < 0.05). In, fact this decrease in the
pSmadS levels, of 0 and 2 Gy PI8 cells were not significantly different from the pSmadB
levels induced by endogenous TGF-pi (Figure 22A and B). However, the exogenous
TGF-pi-induced pSmadS levels did not decrease significantly in 2 Gy P8 cells.
Therefore the alteration in pSmadS levels occurred as a result of repeated subculturing
but not due to radiation exposure. On the other hand, the inherent levels of Smad3 did
not change significantly among irradiated and non-irradiated early and late passages,
regardless of the addition of exogenous TGF-pl (Figure 22A and C). Also, there were no
significant differences in the levels of Smads4 and 7 in cells that were early and late
passage cells plus/minus irradiation (Figure 23A and B).
Collectively, the results indicate that activity levels of Smads2 and 3 were altered
after radiation and repeated sub-culturing. However, their inherent levels, and the
inherent levels of Smads4 and 7, were not altered under these conditions. Therefore, if
the TGF-pi signaling pathway is contributing to the changes observed in our cell line as a
result of radiation and repeated sub-culturing, it may be occurring at the level of the
Smads (pSmads2 and 3).
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Figure 21. pSmad2 and Smad2 levels as a function of repeated sub-culturing and
radiation. A) Immunoblotting experiments were performed in irradiated and nonirradiated FRTL-5 cells (P8 and 18). Cell lysates were separated on SDS-PAGE and
protein levels were detected using a rabbit and goat polyclonal antibody and to pSmad2
(upper blot) and Smad2 (middle blot) respectively. A mouse monoclonal antibody to (3actin was used as an internal control (lower blot). pSmad2 (B) and Smad2 (C) blots were
scanned and the densitometer results were recorded using the Alpha Imager. The results
are represented as mean +/- SE (standard error) of two independent experiments.
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Figure 22. pSmad3 and Smad3 levels as a function of repeated sub-culturing and
radiation. A) Immunoblotting experiments were performed in irradiated and nonirradiated FRTL-5 cells (P8 and 18). Cell lysates were separated on SDS-PAGE and
protein levels were detected using rabbit polyclonal antibodies and to pSmad3 (upper
blot) and Smad3 (middle blot) respectively. A mouse monoclonal antibody to (3-actin was
used as an internal control (lower blot). pSmad3 (B) and Smad3 (C) blots were scanned
and the densitometer results were recorded using the Alpha Imager. The results are
represented as mean +/- SE (standard error) of two independent experiments.
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Figure23. Densitometer results for Smad4 (A) and Smad? (B). Irradiated and nonirradiated FRTL-5 cell (P8 and 18) lysates were separated on SDS-PAGE and protein
levels were detected using mouse monoclonal to Smad4 and rabbit polyclonal antibodies
and to Smad? respectively. A mouse monoclonal antibody to (3-actin was used as an
internal control. The blots were scanned and the densitometer results were recorded using
the Alpha Imager. The results are represented at mean +/- SE (standard error) of two
independent experiments.
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Evaluating the Role of Endogenous and Exogenous TGF-pl in the Transcriptional
Activation of Cyclin A and PAI-1
It is widely known that TGF-f31 functions to arrest cell cycle progression by
decreasing the production of cyclin A (Feng et ah, 1995; Gomperts et ah, 2003; Henglein
et ah, 1994; Pardali & Moustakas, 2006). TGF-(31 also functions to increase extracellular
matrix deposition by increasing the levels of plasminogen activator inhibitor type 1 (PAI1) (Wrana et ah; 1992, Nicolussi et ah, 2003). Since it appeared that radiation and
repeated sub-culturing altered Smads2 and 3 activities, we determined whether TGF-pl’s
role in the regulation of transcription was altered, which may indicate whether changes
observed in these Smad activities contributed to the alterations we observed.

Two

plasmids (pGL3-CAL and pGL3-PAI) were utilized to determine whether TGF-pl’s
effect on transcriptional activation of these two effectors was altered due to radiation and
repeated sub-culturing.
A series of experiments were conducted to optimize the method of transfection
used on our cells. We conducted all our optimizing experiments in un-irradiated early
passage cells (P8-P10). As mentioned previously (see Materials and Methods), we used
the Effectene method to introduce the plasmids into our cells. In order to determine the
best quantity of DNA and the optimum DNA to Effectene ratio suitable for our system,
we conducted a series of experiments with varying quantities of DNA combined with
varying DNA to Effectene ratios. The pRL-TK plasmid was used for these experiments.
The combination chosen for our experimental conditions was a DNA quantity of 0.4 pg
along with a DNA to Effectene ratio of 1:25 (Figure 24A). This was due to the fact that
we obtained very high RLU signal comparable to that obtained when 0.4 pg of DNA was
used along with a 1:50 DNA to Effectene ratio.
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Another series of experiments were conducted to determine the ideal co
transfection ratio of test pGL3-CAL (containing the firefly luciferase reporter gene) to
pRL-TK, a plasmid that contains the renilla luciferase reporter gene. The ratio of 10:1
(firefly to renilla ratio) proved to be ideal for our experiment (Figure 24B) because, at
this ratio, the possibility of the trans effect occurring when the plasmids were co
transfected together was lessened. At the same time, we were still able to express the
pRL-TK at a moderate intensity (roughly half that of our test plasmid). This ratio was
also used in our subsequent experiments involving pGL3-PAI co-transfected with pRLTK.
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Figure 24. Optimizing the parameters for transfection. A) Non-irradiated FRTL-5 cells
were transfected with varying amounts of DNA and varying DNA to Effectene ratios.
The DNA quantity of 0.4pg and the DNA to Effectene ratio of 1:25 was determined as
optimal for our experimental conditions. B) Non-irradiated FRTL-5 cells were
transfected with varying ratios of pGL3-CAL:pRL-TK (firefly:renilla). The optimal ratio
was 10:1. Results are represented at mean +/- SE (standard error) of triplicate samples.
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□

50:1

The next set of experiments was intended to determine the best concentration of
TGF-J31 that would promote its effect on inhibiting the transcription of cyclin A. As
shown in Figure 25, the concentration of TGF-f31 that inhibited cyclin A transcription to
roughly half its normal level was that of lOng/ml. Our findings are supported by
published reports which mention that a concentration of lOng/ml TGF-{31 was suitable
for regulating the transcription of cyclin A and PAI-1 (Feng et ah, 1995; Wrana et ah,
1992; Nicolussi et ah, 2003). This concentration was therefore chosen for our subsequent
experiments involving pGL3-CAL and pGL3-PAL
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Figure 25. Determining the correct concentration of TGF-pi for experimental use. Nonirradiated FRTL-5 cells were transfected and later treated with varying doses of TGF-|31.
The TGF-pl concentration of lOng/ml was determined as optimal for our experimental
conditions. Results are represented at mean +/- SE (standard error) of triplicate samples.

87

It was also determined from the literature that the suitable incubation time after
addition of TGF-pi was 24 and 48 hrs for cyclin A and PAI-1 respectively. We therefore
used those time points for our experiments. Our last set of optimizing experiments
involved examining whether our plasmids pGL3-CAL and pGL3- PAI-1 were regulated,
as they should, by TGF-(31. Feng et al. had shown, by using the plasmid pCAL2 (which
contains the cyclin A promoter), that TGF-pi caused a decrease in cyclin A
transcriptional activation in Mink lung epithelial cells (MvlLu) (Feng et al., 1995).
Wrana et al. and Nicolussi et al. also successfully showed, by utilizing the plasmid p3TPLux, that TGF-pi functioned to increase transcriptional activation of PAI-1 (in both
MvlLu and FRTL-5 cells) (Wrana et al., 1992; Nicolussi et al., 2003). We verified these
effects of TGF-pi in MvlLu cells using our plasmids and we confirmed that TGF-pl was
indeed functioning to regulate these transcriptional events correctly (Figure 26A and B).
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Figure 26. Confirmation that the pGL3-CAL and the pGL3-PAI are correctly regulated
by TGF-(31. A) MvlLu cells were transfected with pGL3-CAL to evaluate its expression
with or without TGF-pi treatment. B) MvlLu cells were transfected with pGL3-PAI to
evaluate its expression with or without TGF-pl treatment. Results are represented as
mean +/- SE (standard error) of triplicate samples.
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Additionally, we confirmed these results in our un-irradiated early passage FRTL5 cells (data not shown). From these experiments we determined that by using these
plasmids we would be able to detect whether treatment by radiation exposure or by
repeated sub-culturing caused the alteration in TGF-pi’s role in regulating the
transcription of cyclin A and PAI-1.
After thoroughly standardizing the experimental conditions, two crucial
experiments were conducted. The first involved determining whether irradiation and
repeated sub-culturing contributed to altering TGF-pi’s role as a cell cycle inhibitor by
way of deregulating cyclin A promoter activity. The pGL3-CAL contains the TGF-(31
regulated cyclin A promoter placed upstream from the firefly luciferase reporter gene. A
decrease in luciferase activity indicates that TGF-pi is functioning normally to promote
cell cycle arrest by inhibiting cyclin A production. As expected, the addition of TGF-{31
decreased the cyclin A promoter activation significantly (indicated by a decrease in
luciferase activity) in un-irradiated control cells (OGy P8 cells) (p < 0.005) (Figure 27).
Flowever, in cells that were irradiated and repeatedly sub-cultured, TGF-f31 did not
trigger a decrease in cyclin A production. In fact it promoted rather than inhibited cyclin
A promoter activation under these conditions, especially at the later passages (Figure 27).
This increase in TGF-(31 induced cyclin A promoter activity was significant at 2 Gy P8, 0
Gy PI8 and 2 Gy PI8 when compared to 0 Gy P8 (control). A significant increase in
TGF-pi induced activity was also seen in 2 Gy PI8 + TGF-|31 compared to 2 Gy PI8 TGF-pi. There were, however, no significant changes in the cyclin A promoter activity
in the absence of exogenous TGF-pi.
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The next set of experiments we conducted was to determine whether TGF-pi’s
ability to induced PAI promoter activity was altered due to radiation and repeated sub
culturing. TGF-pi normally causes an increase in the expression of PAI-1, which
regulates ECM accumulation. The pGL3-PAI contains the TGF-pi inducible the PAI-1
promoter placed upstream from the firefly luciferase gene. An increase in luciferase
activity indicates that TGF-pi is functioning normally to enhance extracellular matrix
production by increasing the levels PAI-1. As expected, the addition of exogenous TGFpi caused a significant increase in PAI transcriptional activity (as indicated by an
increase in luciferase activity) (Figure 27A) in 0 Gy P8 cells (p < 0.001). Radiation had
no effect on altering TGF-pl’s induced activity. However, TGF-pi-induced increase in
luciferase activity was further enhanced as a result of repeated sub-culturing (0 Gy PI 8; p
< 0.05 compared to OGy P8) which suggest that repeated sub-culturing, but not radiation,
played a role in enhancing PAI-1 transcriptional activity (Figure 28A). In order to
confirm these results, we examined the PAI-1 protein levels of the FRTL-5 cell lysates
and supernatants via PAI-1 ELISA (Figure 28B). The addition of exogenous TGF-pi
enhanced PAI-1 production significantly in both cell lysates and supernatants when
compared to PAI-1 produced by endogenous TGF-(31 (p < 0.001). The quantity of PAI-1
protein produced and secreted by our cell (supernatants) was significantly greater than the
quantity that remained inside the cell (cell lysates) regardless of whether or not
exogenous TGF-(31 was added. Nevertheless, it was even more evident that repeated sub
culturing, and not radiation, contributed to a greater enhancement of TGF-(31 induced
PAI-1 production (p < 0.001). This was true for PAI-1 measured in both the cell lysates
and the supernatants and this observed trend was independent of whether or not
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exogenous TGF-pi was added (Endogenous TGF-pi did not cause this similar trend at
the transcriptional level). Therefore, the ELISA results confirmed our transfection
results.
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Figure 27. TGF-pi regulation of cyclin A in irradiated and non-irradiated P8 and PI8
FRTL-5 cells. The pGL3-CAL plasmid was co-transfected with the pRL-TK plasmid
(10:1) early and late passage cells plus/minus radiation using Effectene. The cells were
recovered in media with serum and then the media was replaced with serum-free media.
Cells were subsequently treated with TGF-pi for 48 hrs, after which, the promoter
activity was measured by luciferase activity. Transfection efficiency for luciferase
activity was normalized to renilla luciferase (pRL-TK) activity. Results are represented
as ratios of fireflyirenilla luciferase activity. Each value represents mean +/- S.E. from six
independent transfections.
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Figure 28. TGF-|31 regulation of PAI-1 in irradiated and non-irradiated P8 and P18
FRTL-5 cells. A) The pGL3-CAL plasmid was co-transfected with the pRL-TK plasmid
(10:1) into early and late passage cells plus/minus radiation using Effectene. The cells
were recovered in media with serum and then the media was replaced with serum free
media. Cells were subsequently treated with TGF-(31 for 24 hrs, after which, the
promoter activity was measured by luciferase activity. Transfection efficiency for
luciferase activity was normalized to Renilla luciferase (pRL-TK) activity. Results are
represented as ratios of firefly:renilla luciferase activity. Each value represents mean +/S.E. from six independent transfections. Irradiated and non-irradiated cells, cultured in
100mm flasks, were treated with TGF-|31 for 24 hrs. The cell lysates (B) and
supernatants (C) were then harvested and PAI-1 was quantified by the rat PAI-1 ELISA
kit. Each value represents mean +/- S.E. from two independent experiments.
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CHAPTER FOUR
DISCUSSION
The objective of this study was to examine the role of TGF-(31 production,
recognition and response, to determine whether it contributed to the changes observed in
FRTL-5 cells as a function of repeated sub-culturing or by the acceleration of these
processes following radiation. To date, not many studies have been conducted in FRTL5 cells to determine how radiation and/or repeated sub-culturing alter the role of this
cytokine and the other players in its signaling pathway. From our study, we have
discovered the following: 1) The relative rate of cell division increased from P8 to P18
for both irradiated and non-irradiated cells and radiation exposure induced an
acceleration in the rate of cell division; 2) There were significant increases in the levels
of total TGF-(31 in late compared to early passage cultures (Figure 14) and a similar
pattern was also evident in irradiated compared to non-irradiated early passages; 3) The
levels of TGF-(31 were independent of dose, increased with time subsequent to radiation
exposure; 4) There were no significant differences in the T(3RI and TpRII levels or in
their ratios in irradiated and/or repeatedly sub-cultured cells compared to non-irradiated
early passage cells; 5) The addition of exogenous TGF-J31 contributed to significant
increase in Smad2 phosphorylation but to a lesser extent in irradiated and/or repeatedly
sub-cultured cells when compared to 0 Gy P8 control cells. This decrease in
phosphorylation was due to a combined effect of radiation exposure and repeated sub
culturing; 6) The addition of exogenous TGF-pl contributed to an increase in Smad3
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phosphorylation but to a lesser extent in irradiated and/or repeatedly sub-cultured cells
compared to 0 Gy P8 control cells. This decrease in phosphorylation was due to repeated
subculturing and not as a result of radiation exposure; 7) There were no significant
differences in the inherent levels of Smads2, 3, 4 and 7 in early and late passage cells
plus/minus radiation; 8) The addition of TGF-pi caused a decrease in cyclin A promoter
activation in un-irradiated control cells but not in cells that were irradiated and/or
repeatedly sub-cultured, where it promoted rather than inhibited cyclin A promoter
activation under these conditions; and 9) The addition of exogenous TGF-pi promoted an
increase in PAI-1 transcriptional activity and in the PAI-1 protein levels of our cells,
which was further enhanced by repeated sub-culturing but not by radiation exposure.

The Impact of Radiation and Repeated Sub-culturing
on the Rate of Cell Division
Our findings that the relative rate of cell division is increased as a result of
repeated sub-culturing is supported by previously published results from our laboratory
(Green et ah, 2001a). We showed that later passages (PI7 and P20) of FRTL-5 divided
faster than earlier passages (P6 and PI3). We discovered that these differences in the
rate of cell division were linked to the expression of functional Cx32. Earlier passages
expressed functional Cx32 and divided on an average every 49 hrs similar to primary
thyroid cells. However, later passages (PI7 and beyond) developed a mutation (a point
deletion) in the cytoplasmic loop region at nucleotide 378 corresponded to the middle
position of the codon for amino acid 116. The deletion caused a frame-shift converting
the histidine at amino acid 116 to a proline. Four amino acids past the deletion, a
premature stop codon resulted in truncation of the remaining 60% of the protein and
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hence non-functional gap junctions in the late passage cells.

Because of this non

functional truncated Cx32 present in later passage cultures, there was a loss of
communication via gap junctions which resulted in accelerated growth rate, reduced
follicularization and reduction in thyroxin release (Green et ah, 2001a).
From the data we collected comparing early to late gamma-irradiated cell
cultures, our qualitative observations were that irradiated early passage cells displayed an
accelerated growth rate comparable to that of late passage cells. However, we had not
quantified these changes until recently. From this study we were able quantitatively
confirm that radiation accelerated the relative rate of cell division in FRTL-5 cells that
were repeatedly sub-cultured from P8 to P18 (Figure 13). These observations are
consistent with those of Riches et al, who demonstrated that the human retinal pigment
epithelial cell line (340RPE-T53), immortalized by treatment with telomerase, displayed
a marked increase in growth rate in vitro after exposure to ten fractionated dose of 2 Gy
gamma radiation when compared to the parent cell line. This increase in cell growth was
consistent with neoplastic transformation which occurred in 340RPE-T53 (Riches et al.,
2001). We can therefore suggest from these findings that the changes in the phenotypic
characteristics observed in our cell line as a result of radiation and/or repeated
subculturing may be similar to transformed cellular characteristics observed in potentially
malignant cells and may have implications in radiation induced carcinogenesis and in
vitro malignant conversion.
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The Impact of Radiation Exposure and Repeated Sub-culturing
on the Protein Levels of TGF-pl
The fact that later passages of FRTL-5 cells secreted more basally active, total
and latent TGF-|31 than earlier passage cells is supported by research conducted with
human fetal glomerular mesangial cells (FMC2) (Schnaper et ah, 1996). However,
instead of measuring the protein levels of the cytokine, changes in TGF-(31 mRNA
expression levels were documented. TGF-pl mRNA levels were found to increase 5-fold
in later passes (PI6) compared to earlier ones (P8). These results supported an increase
in TGF-pi production with serial passage. These results also support the conclusion that
prolonged serial passage of several cell types in culture lead to increased production of
ECM proteins indicative of fibrotic changes associated with repeated sub-culturing
(Schnaper et ah, 1996). There are many reports which state that radiation induces
activation of latent TGF-pi (Barcellos-Hoff & Costes, 2006; Barcellos-Hoff & Brooks,
2001; Barcellos-Hoff, 1996; Barcellos-Hoff et ah, 1994, Barcellos-Hoff, 1993; Green et
ah, 2002; Kim et ah, 2002; Yin et ah, 1999; Ehrhardt et ah, 1997). These reports also
emphasize that radiation exposure causes an increase in the levels of active, latent and
total TGF-pi. Our data support these findings which indicate that our FRTL-5 cells are
responsive to radiation. Measurement of the TGF-pi protein levels also indicated that
radiation induced the production of TGF-(31 in a radiation dose independent manner but
that the levels of TGF-(31 increased with time. Others, however, have shown that TGFpi induction subsequent to low-dose radiation is dose dependent up to a maximum of 0.5
Gy of cobalt-60 gamma-ray exposure in endothelial cells (Rodel et ah, 2002). This dosedependency was also observed by O’Malley et al, up to 5 Gy colbalt-60 gamma ray
exposure in mammary epithelium (Davis et ah, 1986). However in support of our data,
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experiments, done by Gridley et al. showed that C57 BL/6 mice, that received wholebody gamma irradiation, had elevated plasma levels of TGF-(31, which were not
dependent on the dose of radiation used (0.5, 1.5 and 3.0 Gy) (Gridley et ah, 2001).
Wang et al. also demonstrated, in rat mesangial cells exposed to 5-20 Gy gamma
radiation, that TGF-(31 mRNA levels increased in a dose independent manner with time
(from 24 to 48 hrs after radiation) (Wang et al., 2003). Other evidence has shown that
radiation also invokes an increase in TGF-|31 at the mRNA level (O’Malley et al., 1999).
The discovery that radiation induced-TGF-pi protein levels increased with time was
further endorsed by results published from our laboratory group wherein, we quantified
the levels of TGF-|31 in flask and bioreactor tissue analogs via TGF-pi ELISA (Green et
al., 2002). A possible reason for variations in the findings of these dose and time
experiments is that TGF-pl is produced and regulated in a cell and tissue dependent
manner. To date, we are the first to report the effects ionizing radiation and/or repeated
sub-culturing on TGF-f31 production in our cell line. Our data suggests that TGF-(3 may
be linked to physical changes resulting in the premature expression of phenotypic
characteristics (evident in late passage cells) displayed in early passage cells exposed to
radiation. Therefore, if TGF-|31 played a role in mediating these changes in cellular
properties, then the function of the players in its signaling pathway must altered from
growth inhibition to growth promotion. This led us to investigate the other factors in the
TGF-pi signaling pathway.
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The Involvement of the TpRI and TpRII in
Altered TGF-pi Signaling
From quantifying the protein levels and ratios of Tf3RI and TpRII, we deduced
that radiation and/or repeated sub-culturing did not result in significant changes in the
levels of the receptors or in the ratios of TpRI to TpRII. Based on published results from
several laboratories, a common deficiency that contributed to abnormal responses to
TGF-pi was at the level of the receptors. Thus we thought that this was a starting point
for our investigations. Studies conducted by Coppa et al. showed that a reduction in
TpRII mRNA and protein levels, with no change in the TpRI levels, contributed to an
altered signaling pathway in transformed FRTL-5 cells (Coppa et al., 1997). Kim et al.
have also showed that a reduction in the expression of TpRI may cause alterations in the
TGF-pi signaling in transformed prostate cells, (Kim et al., 1996). Reports on MCF-7
early and late cells (breast cancer cells) documented that late passage cells were resistant
to TGF-pi partly due to decreases both in the mRNA and protein levels of TpRII
compared to earlier passages. They also demonstrated that there were no changes evident
in the TpRI levels under similar experimental conditions (Ko et al., 1998; Liu et al.,
2000). There are various reasons why we did not observe a reduction in the levels of
TpRII under our experimental conditions. It is possible that the dose of gamma radiation
was not high enough to evoke a reduction in the expression of the receptors, particularly
TpRII. It is also possible that a reduction in the levels of these receptors may not be
evident at pass 18 but may be seen at passes later than this. The data therefore suggests
that FRTL-5 cells may have begun to display phenotypic characteristics that indicate the
beginning of cell transformation but may not be at the stage where they are fully
transformed. The phenomenon may occur at very late passages. It is also important to
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note that modifications may occur in the TGF-|3 receptor genes, which lead to changes in
the phosphorylation sites which would prevent them from functioning normally to
transmit the TGF-(31 signals. This could occur without a concomitant a change in
expression or ratios of the surface receptors.

The Involvement of the Smads in Altered TGF-pi Signaling
Our results show that the steady state levels of Smads2, 3, 4 and 7 were not
significantly altered after radiation and repeated subculturing regardless of whether
exogenous TGF-|31 was added. However, the levels of pSmads2 and 3 were lower in
irradiated and/or repeated sub-cultured cells treated with exogenous TGF-(31 compared to
the 0 Gy P8 control cells. Nindl et al. noted that there were no significant changes in the
Smads 2 and 4 mRNA levels among the different stages (early mortal, late mortal, early
immortal and late immortal) of two human keratinocyte cell lines (FK16A and FK16B)
(Nindl et al., 2003). These results correspond with our data even though they measured
the mRNA instead of the protein levels. It is highly likely that, although we did not
observe changes in the Smad4 protein levels, there may have been differences in the
localization patterns of this Smad, especially when it forms a complex with Smads2 and
3. It would therefore be best to examine the cytoplasmic vs nuclear localization patterns
of the Smad complex to determine whether alterations exist which would prevent the
complex from acting on transcription in the regulation of TGF-pl response genes.
Hageman et al. also showed that even though TGF-(31 induced increase in the Smad?
gene expression, radiation did not cause a significant increase in the levels of this Smad
(Hageman et al., 2005). Our finding regarding the effect of radiation on Smad? levels
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agree with these results. However, our findings which show that there were no TGF-|31
induced changes in Smad7 differ from those of Hageman et al. Barcellos-Hoff indicated
that radiation exposure caused an increase in the levels of protein Smads2 and 3
(Barcellos-Hoff, 2005, Ewan et ah, 2002). Others have suggested that the levels of
pSmads2 and 3 increase as a result of radiation injury which leads to radiation induced
fibrosis (Xavier et al, 2004). A possible reason for the reduction in the levels of pSmads2
and 3 (while their steady state levels remain the same) in irradiated and repeatedly sub
cultured cells could be due to the fact that these conditions induce missense or nonsense
point mutation in the MH2 domain of these Smads, which prevent them from becoming
phosphorylated by Tf3RI. Mutations may also develop in the L3 loop of the MH2 domain
which may prevent these R-Smads from associating with TpRI. Other changes may
inhibit the process of R-Smad dissociation from T(3RI after they are phosphorylated.
These mutations may lead to protein instability, which could in turn lead to rapid
degradation of the R-Smad and as a result, affect TGF-(31 signaling. It should also be
noted that even though the levels of Smads4 and 7 were unaltered as a result of radiation
and/or repeated sub-culturing, mutations may have developed which alter their function.
Further investigations involving the search for mutations or structural alterations are
necessary to determine whether these changes occurred as a result of radiation and/or
repeated sub-culturing which may contribute to alter TGF-f31 signaling.
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The Impact of Radiation and Repeated Sub-culturing on the TGF-pi Induced
Transcriptional Activation of Cyclin A and PAI-1

Since it has already been reported that TGF-pl functions to arrest cell cycle
progression by decreasing the production of cyclin A (Feng et ah, 1995, Gomperts et ah,
2003, Henglein et ah, 1994, Pardali & Moustakas, 2006) and increasing extracellular
matrix deposition by increasing the level of PAI-1 (Wrana et ah, 1992, Nicolussi et ah,
2003), we utilized plasmids containing the promoter regions of these two TGF-(31
response genes to determine whether radiation and/or repeated sub-culturing altered
TGF-pi role in regulating these two factors.

Cyclin A Promoter Regulation
Our results using the pGL3-CAL plasmid showed that the addition of exogenous
TGF-pi caused a decrease in cyclin A promoter activation in un-irradiated control cells.
However, TGF-(31 failed to inhibit cyclin A promoter activity in cells that were irradiated
and/or repeatedly sub-cultured. In fact, it enhanced, rather than inhibited, cyclin A
promoter activation under these conditions. Significance in its altered function to
increase cyclin A promoter activity is evident in 2 Gy P8, 0 Gy PI8 and 2 Gy PI8 cells.
Therefore, TGF-fPs function switched from an inhibitor to that of a cell cycle promoter
after radiation and repeated sub-culturing.

Studies have shown that cells normally

divide a finite number of times, after which they become senescent (Goberdhan et ah,
1994; Hayflick & Moorehead, 1961; Hayflick, 1965) and according to Toussaint et al.,
telomere-dependent senescence is the ultimate barrier against cell immortalization
(Toussaint et al., 2002). This is not the case for the FRTL-5 thyroid epithelial cells as our

104

results indicate that these cells become immortalized and subsequently transformed as a
result of radiation and repeated subculturing.
TGF-pi and some downstream effectors in its signaling pathway (e.g.
T|3RII and Smads2, 3 and 4) are tumor suppressors that normally prevent cell
immortalization leading to cancer. One of the ways in which they accomplish this is by
triggering the cells to undergo in vitro senescence (Vijayachandra et al., 2003). When
TGF-(31 and the players in its signaling pathway are deregulated, they no longer serve to
promote senescence and as a result, normal cells may become immortalized and
subsequently transformed into malignant cells (Fleish et al., 2006; Vijayachandra et al.,
2003; Pardali & Moustakas, 2007). TGF-pi has also been shown to promote cell cycle
progression and thus trigger growth promotion, which normally occurs in metastatic
tumors (Pardali & Moustakas, 2007). Our results suggest that as FRTL-5 cells are
repeatedly sub-cultured, they become immortalized and assume an increasingly
transformed phenotype. This may be due to the fact that TGF-pl fails to promote
permanent cell cycle arrest (senescence) at later passages and instead, promote cell cycle
progression and increased cell proliferation. It is also possible that under our
experimental conditions, TGF-pi’s role has switched from a cell cycle inhibitor to a cell
cycle promoter, thus promoting cell immortalization and transformation. The results also
suggest that gamma radiation functions to accelerate the onset of cell immortalization and
pre-transformation. Investigation of molecules regulated by TGF-pi such as other
cyclins, cyclin dependent kinases, cyclin dependent kinase inhibitors, other tumor
suppressors (e.g. Rb) and oncogenes (e.g. c-Myc) in future studies will confirm whether
TGF-pi’s function was repressed or switched as a result of radiation and/or repeated sub-
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culturing. Other pathways, such as the MAPK pathways (ERK-mediated pathways, JNK
and p38-signaling pathways), may also influence cell cycle progression with or without
TGF-pl involvement. It would therefore be important to investigate the players in these
pathways to determine whether they influence cell cycle progression in FRTL-5 cells.

PAI-1 Promoter Regulation
Our results using the pGL3-PAI plasmid showed that the addition of exogenous
TGF-pi caused an increase in PAI-1 promoter activation in un-irradiated control cells,
which was further enhanced by repeated sub-culturing but not by radiation exposure.
Radiation-induced fibrosis is an important side effect of radiation therapy in the treatment
of cancer. One of the molecules implicated in radiation-induced fibrosis is PAI-1, which
functions to enhance extracellular matrix accumulation by inhibiting the plasminogen
activators urokinase plasminogen activator (u-PA) or tissue-type plasminogen activator
(t-PA). Both u-PA and t-PA are capable of converting the inactive zymogen plasminogen
to the active proteinase plasmin, which degrades most extracellular proteins (Andreasen
et ah, 1997; Higgins, 2006). Studies have shown that radiation causes an increase in the
mRNA levels of PAI-1 (Milliat et ah, 2006; Zhao et ah, 2000). This increase in PAI-1
levels was found to be dose dependent (Zhao et al., 2000). Hageman et al. also
investigated the effect of different doses of gamma-radiation on PAI-1 induction in
MvlLu cells with or without the addition of exogenous TGF-pi. They discovered that
TGF-pi and radiation showed strong cooperative effects in inducing PAI-1 transcription
(Hageman et al., 2005). Radiation was also shown to promote a dose dependent induction
in PAI-1 regardless of whether exogenous TGF-(31 was added. This dose dependent
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effect was also evident irrespective of whether there was activation of latent TGF-pi. The
results, obtained at the 2 Gy dose in our study were similar to the results they obtained.
At 2 Gy, radiation did not promote an enhanced PAI-1 induction with or without the
addition of exogenous TGF-f31. Significant effects of radiation were only observed at
doses from 8-32 Gy. They also discovered that when four fractionated doses of 2 Gy
were administered over a four day period, there were significant radiation-induced
increases in PAI-1 activation. This was further enhanced significantly when TGF-pl was
administered along with the fractionated doses. Therefore, a 2 Gy dose of gamma
irradiation only has implications in radiation-induced fibrosis, when it is administered as
a fractionated dose instead of as a single dose. In order to determine that the effect of
gamma-radiation was stimulating increases in PAI-1 production in FRTL-5 cells it would
be better to investigate the effects of fractionated rather than single doses of radiation.
Our results show that repeated sub-culturing results in PAI-1 induction at the
transcription and protein levels and is consistent with those of Mu et al. and Schnaper et
al. in their experiments with human diploid fibroblasts (IMR-90) and glomerular
messangial cells (FMC2), respectively. However, they have linked the increase in PAI-1
levels to in vitro aging which occurs in their late passage cells (Mu et al., 1998; Schnaper
et al., 1996). Other reports suggest that increased PAI-1 production is implicated in cell
immortalization, transformation and tumor metastasis (Andreasen et al., 1997;
Chorostowska-Wynimko et al., 2004; Romer et al., 2005). To date, the data we have
gathered suggest that our cells do not display senescent-like characteristics; instead, the
phenotypic changes associated with repeated sub-culturing are similar to those of cells
becoming immortalized and thus transformed. Therefore, our results are consistent with
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those which show an enhanced PAI-1 production in cells which are immortalized and
transformed. It is also interesting to note that the combined effect of radiation and
repeated sub-culturing enhanced PAI-1 production, but to a lesser extent than the effect
of repeated sub-culturing alone. Therefore, it is possible that the radiation effect (at late
passages) may be functioning antagonistically to lessen PAI-1 production rather than to
further enhance it. The exact mechanism for this is not currently understood and, to date,
no other research group has investigated this scenario. Other experiments concerning
molecules involved in ECM accumulation and degradation would greatly aid in
determining whether radiation and/or repeated sub-culturing function to control ECM
turnover and whether this control is enhanced by TGF-pi. We would, thus, gain insight
into whether these molecules are assisting in the development of a transformed phenotype
associated with radiation and/or repeated sub-culturing.

Conclusion
Overall, our results suggest that TGF-pi is contributing to the alterations we
measured in our cells as a result of radiation and with repeated sub-culturing. The
results indicate that the late passage cultures were producing 2.3-fold more total TGF-pi
than early passage cultures (p < 0.05). Our findings also show that radiation-induced
production of TGF-pi was also roughly 3-fold (p < 0.05) similar to the differences we
measured when we compared non-irradiated early to late passage cells. Our data
therefore suggested that TGF-pi was linked to the physical changes observed in or cells
under our experimental conditions, resulting in the onset of cellular transformation.
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Our investigations involving TGF-pi’s regulation of the cell cycle showed that its
normal function to inhibit cell cycle progression was altered as a result of radiation and
repeated subculturing. It contributed to triggering cell cycle progression by significantly
promoting (p < 0.005), rather than inhibiting, cyclin A expression under these conditions.
As a result there was a significant increase in the growth rate of irradiated and repeatedly
sub-cultured cells (p < 0.05) which indicated that our cells assumed a pre-transformed
phenotype because TGF-pi’s normal function to regulate cell cycle progression, and
ultimately preventing cell transformation, was altered.
We observed enhanced PAI-1 promoter activity and protein levels (p < 0.05),
under our experimental conditions, which is also implicated in cells undergoing
immortalization and transformation. This further implies that alterations occurred in the
TGF-(31 signaling pathway which promoted cell transformation as a result of radiation
and repeated subculturing.
No changes were observed in the levels of T(3RI and T(3RII and in the ratio of
T(3RI to T(3RII as a result of radiation and repeated subculturing which suggest that the
alterations, occurring in the TGF-(31 signaling pathway under these conditions, were not
at the level of the receptors. Even though there were no significant changes in the
inherent levels of Smads2, 3, 4 and 7, the levels of activated Smads2 and 3 were reduced
post radiation and repeated subculturing (p < 0.05). These findings may be associated
with the increase in cyclin A promoter activation and enhanced PAI-1 production.
Confirmation of Smad involvement would therefore be of interest in the future.
Even though this study gives us partial insight into the mechanism by which our
cells respond to the effects of radiation and repeated sub-culturing, our findings indicate
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that TGF-pi is contributing to the alterations we measured in our cells under these
conditions. Clearly, additional studies are warranted to advance the field and to further
determine the mechanism by which radiation and repeated sub-culturing affect and alter
TGF-(31 signaling in FRTL-5 cells. By our accomplishments and future studies, we will
better understand these mechanisms and be able to use our cell line as a model to study
radiation-induced diseases and processes involved in tumorigenesis.

Future Studies
Our studies have provided insight into the effect of radiation and repeated sub
culturing and some of the alterations, triggered by these insults leading to modifications
in the TGF-f31 pathway in our thyroid epithelial FRTL-5 cells. However, additional
studies are needed to further our understanding of the effect of these parameters on
deregulating the components involved in the pathway and responses to TGF-|31. Studies
should be conducted to confirm whether FRTL-5 cells become transformed and are
tumorigenic with repeated sub-culturing and whether radiation accelerates the onset of
this phenotype. This may be done by injecting the cells into athymic mice and observing
whether they develop into tumors.
We need to obtain a more in depth understanding of whether radiation and
repeated sub-culturing alter the TGF-|31 signaling pathway by way of Smad complex
formation and subsequently by affecting the function of the Smad complex in regulating
the transcription of TGF-pi response genes (e.g. cyclin A and PAI-1). Coimmunoprecipitation experiments can be performed to determine whether the R- Smads
and C-Smad are associating with each other to form the Smad complex.
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Immunocytochemistry experiments should also be conducted to determine the location of
and translocation of the Smad proteins. High levels of these Smad proteins in the nucleus
may give a positive indication that, after stimulation by TGF-(31, the Smad complex is
trafficked to the nucleus where they can act as transcription factors and regulate the TGFpi response genes. An accumulation of these proteins in the cytoplasm would be an
indication that the Smad complex may not have formed or that the resulting complex
could not be trafficked to the nucleus to engage in transcription. These findings would
aid in determining where alterations are occurring in the pathway. The possibility exists
that alterations may modify the ability of the Smad complex to interact with co-activators
e.g. CBP and p300, co-repressors e.g. Ski and SnoN and with the transcription response
elements (TRE) as a result of radiation and/or repeated subculturing. A thorough
investigation of this possibility awaits future studies. Co-immunoprecipitation studies,
electrophoretic mobility shift assays and/or TRANS AM ELISA (transcriptional factor)
assays would also enhance a full understanding of the possible interacting mechanisms.
It is already known that the TGF-f31 pathway cross talks with other pathways such
as the MARK pathways via the Smad proteins. It would be interesting to study whether
these pathways are functioning to regulate Smad activation in response to radiation and
repeated sub-culturing. Western blot experiments intended to measure the
phosphorylation levels of these molecules would be necessary. Other assays that
measure the activities of these accessory proteins and potential factors would also prove
useful in fully deducing the level of change occurring as a result of cellular injury.
To further determine whether TGF-pi’s ability to arrest cell cycle is altered due to
radiation and repeated sub-culturing, it would be important to study other molecules
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involved in cell cycle regulation e.g. cyclins E, D and B, CDK2, 4 and 6, the CKIs
(plS™, p21 CIP/WAFl and p27KIP1), the Rb family members, c-Myc and the transcription
factor E2F. By investigating the mRNA and protein levels of these cell cycle regulators,
we will be better able to determine whether they are induced by radiation and repeated
sub-culturing. Co-immunoprecipitation EMSA assays may also be conducted to
determine protein-protein and protein-DNA interactions to investigate whether these
associations are altered by radiation and repeated sub-culturing. The quantification of the
phosphorylation levels of some of these players may be necessary to depict changes in
activity caused by radiation and/or repeated sub-culturing.
Lastly, it would be interesting to conduct the studies, previously mentioned, at
different doses of gamma radiation to determine whether these effects vary with dose.
Studies done using different types of ionizing radiation will also aid us in understanding
whether these radiation effects vary depending on the type of radiation. These studies
would contribute to deducing the exact mechanism by which TGF-|31 functions in our
cell line and would also enlighten as to how radiation and repeated sub-culturing are
altering and controlling mechanisms of cellular homeostasis.
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APPENDIX I
Quantification of TGF-pi Ligand Levels in Irradiated and
Non-irradiated P 8-18 FRTL-5 Cells
In the course of conducting our radiation experiments we found that the properties
of the surviving gamma-irradiated early passage cultures resembled late passage cells.
This led us to measure the concentrations of TGF-P in the supernatant taken from
irradiated and non-irradiated cultures followed for various passages from pass 8 to pass
18. As we expected, (Figure 29) irradiation caused in an increase in the levels of total
TGF-P 1 in the P7 samples. However, as the cells were sub-cultured through to P9 the
increase was not as prominent. We also observed that, from P10 to 12, the TGF-P 1 levels
were higher for 0 Gy than for 2 Gy supernatants (Figure 29). However, the irradiated
cells reverted to producing more TGF-P 1 than the non-irradiated cells at PI3. From PH
IS no differences were observed in the levels between the two groups.
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Figure 29. Production of total TGF-pi by gamma-irradiated and non irradiated FRTL-5
cells followed for 18 passages. P7 FRTL-5 cells were cultured in T-75 cm2 flasks until
they were 80% confluent. The medium was changed on the day prior to irradiation.
Samples of supernatant were removed at 48 hrs post exposure (2 Gy gamma rays) and
assayed by TGF-pi ELISA. The cells were harvested and supernatants collected over
repetitive passages. The non-irradiated (0 Gy) cells at each passage served as controls.
The TGF-pi concentration, measured in pg/ml, was normalized to the protein
concentration of the supernatant. Results are presented as mean +/- S.E. of triplicate
samples from two independent experiments.
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TGF-pi ELISA Troubleshooting Experiments
The levels of basally active TGF-J31 in our irradiated samples were variable. In
our original preliminary data, the levels of basally active, latent and were easily
measured. However, this changed in the course of the experiments with only minimal
levels of active TGF-pi produced, indicating that the levels of total TGF-(31 measured in
our quantitative assay mostly represented the levels of latent TGF-pl. This suggested
little TGF-J31 activity due to radiation in these FRTL-5 cultures compared to higher levels
of activity observed in our previous data (Figures 30A and B). This led us to test
whether the disparity in the results was due to any changes that we had unknowingly
introduced into our method of cell culturing. To verify that the TGF-f31 basal activity,
previously obtained, was correct and not due to experimental artifact, we repeated
experiments using aliquots of 0 and 5 Gy gamma-irradiated supernatants similar to those
we had previously used to obtain our dose response data. The results we obtained are
shown in Figure BOA). Again we were able to measure active, latent and total TGF-|31 in
both irradiated and non-irradiated samples. However the levels of basally active TGF-f31
obtained from the 0 Gy samples was almost 400 times more than what we obtained
previously and there was not much difference in the basal activity between the irradiated
and non-irradiated samples. Also, the latent and total TGF-f31 levels were lower in the
irradiated than in the non-irradiated supernatants.
In order to rule out the possibility that failure to quantify basally active TGF-J3
was as a result of the radiation being insufficient to invoke such activity, we cultured and
irradiated FRTL-5 cells with 5 Gy gamma-rays, a higher radiation dose than that used for
the continuation series. We also measured TGF-(31 levels in both 0 and2 Gy cells so that
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comparisons could be made. Figure SOB illustrates that radiation resulted in an increase
in TGF-(31 levels however, we were not able to quantify basal TGF-f31 activity even after
exposure to 5 Gy gamma-rays.
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Figure 30. Quantification of the levels of basally active, latent and total TGF-(31 from
gamma-irradiated and non-irradiated FRTL-5 cells. A) Samples of 5 Gy gammairradiated and non-irradiated (0 Gy) supernatants (previously tested in the dose response
experiments) were re-assayed by TGF-(31 ELISA. The TGF-pl concentrations were
recorded as pg/ml. Results are represented as mean +/- S.D. of triplicate samples. B)
Supernatants were harvested from cultured P7 FRTL-5 cultures exposed to 2 and 5 Gy
gamma irradiation. The supernatants were assayed by TGF-f31 ELISA. The TGF-(31
concentrations, measured in pg/ml, were normalized to the cell count. The non-irradiated
(0 Gy) cells passages served as controls. Results are represented as mean +/- S.D. of
triplicate samples.
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After thorough investigation to determine whether the method of culturing these
cells had inadvertently changed, we discovered that previously, our cells were cultured
with Nal, heat inactivated serum, bovine insulin and without antibiotics. We changed
our method by omitting Nal from our culture medium. We also used serum without heat
inactivation, human insulin (bovine insulin was not available for order at the time) and
we added antibiotics to minimize the possibility of cell culture contamination over the
course of continuous passage and/or manipulation. We, therefore, conducted
experiments testing whether the presence or absence of these parameters made a
difference in the production of basally active TGF-(31 by irradiated and non-irradiated
FRTL-5 cells. The results are shown in Figures 31 and 32.. From the data, we observed
that the presence or absence of Nal, antibiotics or the use of heat inactivated vs non —
activated serum and bovine vs human insulin had no effect on increasing the activation of

TGF-pi.
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Figure 31. Quantifying the levels of TGF-|31 in gamma-irradiated and non-irradiated
FRTL-5 cells under various cell culture conditions. A) 2 Gy gamma irradiated and nonirradiated (0 Gy) FRTL-5 cells (PI7) were cultured in media supplemented with either of
the following: Nal + antibiotics, antibiotics only, Nal only and media with neither of
these two additives. At 80% confluency the cells were irradiated with 2 Gy gamma-rays
and un-irradiated cells (0 Gy) served as controls. The cell supernatants were harvested
and assayed by TGF-pi ELISA. The TGF-pl concentrations were recorded as pg/ml.
Results are represented as mean +/- S.D. of triplicate samples. B) P7 FRTL-5 cells were
cultured in regular media supplemented with either non-heat inactivated or heat
inactivated serum. At 80% confluency, the cells were irradiated with 5 Gy gamma-rays
and un-irradiated cells (0 Gy) served as controls. Supernatants were harvested and
assayed by TGF-f31 ELISA. The TGF-(31 concentrations were measured in pg/ml.
Results are represented as mean +/- S.D. of triplicate samples.
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Figure 32. Quantifying the levels of TGF-J31 in gamma-irradiated and non-irradiated
FRTL-5 cells cultured in regular media with either human or bovine insulin. FRTL-5
cells (P8) were cultured in regular media supplemented with either human or bovine
insulin. At 80% confluency the cells were irradiated with 2 Gy gamma-rays and un
irradiated cells (0 Gy) served as controls. The cell supernatants were harvested and the
TGF-pi concentrations were measured in pg/ml. Results are represented as mean +/- S.D.
of triplicate samples.

We continued our troubleshooting experiments using various cell lines (FRTL-5,
H238, HTORI and MvlLu cells) (Figures 33 and 34). We found that none of the cells
lines produced measurable levels of basally active TGF-(31. Therefore, the production of
basally active TGF-|31 by radiation was not cell line dependent.

134

£ Io>
O

LL

Q—

H

<o

=

o

O

X

I-

c

"D
0)
N

O

300
250
A

200
150
i

F

100

Io Sc

50

O

0

o

I

0

5

10

20

Radiation Dose (Gy)

Figure 33. Quantifying the levels of TGF-pi in P8 FRTL-5 cells exposed to varying
doses of gamma-irradiation. A) FRTL-5 cells (P8) were cultured and subsequently
irradiated with 5, 10 and 20 Gy gamma rays. Un-irradiated cells (0 Gy) served as
controls. The cell supernatants were harvested after 48 hrs, the TGF-f31 concentrations
were measured as pg/ml and the values were normalized to cell counts. The data graphed
represented the mean +/- S.D. of triplicate samples.
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Figure 34. Quantifying the levels of TGF-(31 in different cell lines exposed to varying
doses of gamma-irradiation. A) H238 cells (P33) were cultured and subsequently
irradiated with 2 and 3 Gy gamma rays. Un-irradiated cells (0 Gy) served as controls.
The cell supernatants were harvested and the TGF-|31 concentrations were measured as
pg/ml and normalized to cell counts. Results are presented as mean +/- S.D. of triplicate
samples. B) HTORI cells were cultured with or without Nal and subsequently irradiated
with 2 Gy gamma rays. Un-irradiated cells (0 Gy) served as controls. The cell
supernatants were harvested and the TGF-f31 concentrations were measured as pg/ml and
normalized to cell counts. Results are presented as mean +/- S.D. of triplicate samples. C)
MvlLu cells were cultured and subsequently irradiated with 2 Gy gamma-rays. Unirradiated cells (0 Gy) served as controls. The cell supernatants were harvested and the
TGF-|31 concentrations were measured as pg/ml and normalized to cell counts. Results
are represented as mean +/- S.D. of triplicate samples.
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In order to determine whether the difficulty experienced in measuring basally
active TGF-(31 was due to differences in the TGF-pl ELISA kit that were introduced by
the manufacturer, we tested our samples using two different TGF-pl ELISA kits. One kit
was Human TGF-pi ELISA kit while the other was Mouse, Porcine, Rat TGF-pi ELISA
kit, both obtained from R&D systems. As shown in Figure 35, we were not able to
measure basally active TGF-pl when we used either of these kits. Therefore, we
discovered that the differences in the kits were not the reason for our inability to measure
basally active TGF-pi.
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Figure 35. Quantifying the levels of TGF-|31 in irradiated and non-irradiated P8 FRTL-5
cells using two different TGF-pl ELISA kits. FRTL-5 cells (P8) were cultured in
undiluted media and media with 2% serum. The cells were subsequently irradiated with
2 Gy gamma-rays. Un-irradiated cells (0 Gy) served as controls. The cell supernatants
were harvested and assayed using two different TGF-piELISA kits (human and mouse,
rat, porcine). TGF-(31 concentrations were measured as pg/ml and normalized to cell
counts. Results are presented as mean +/- S.D. of triplicate samples.
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We therefore deduced that we would not be able to quantify the levels of all three
forms of TGF-pi as we had previously been able to do. We then shifted our focus to
examining the other components of the TGF-|31 signaling pathway. For our subsequent
experiments, we added exogenous active recombinant TGF-pl so that we would be better
able to study its effect on our cells that were exposed to radiation and repeated sub
culturing.
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APPENDIX II

Figure 36. Sequence alignment of the cyclin A promoter region with the promoter of
pGL3-CAL. The cyclin A promoter region was sequenced using the RV primer 3. The
sequence was aligned with the known cyclin A promoter sequence using Clustal W
multiple alignment method (Biology Workbench 3.2, San Diego Super Computer
Centre).
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CLUSTAL W (1.81) Multiple Sequence Alignment for Cyclin A Promoter
GAGCT C CGTGT TAAATAATT TAT GCACAT TAT TTAATCC TAACAACCATA
GAGCTC CGTGT TAAATAATT TAT GCACAT TAT TTAATCC TAACAACCATA

Cyclin A promoter
pGLS-CAL RV primer 3

TGACTGTAGTTATTAGTCCCTATTAACACATAAGAAAACGGAGAATCGGA
TGACTGTAGTTATTAGTCCCTATTAACACATAAGAAAACGGAGAATCGGA

Cyclin A promotor
pGL3-CAL RV primer 3

**************************************************

GATACTGAAAAACGTGCCCCAGATTTTAGACCTTTGGAAAAAGTCACTTA
GATACTGAAAAACGTGCCCCAGATTTTAGACCTTTGGAAAAAGTCACTTA

Cyclin A promotor
pGLS-CAL RV primer 3

AGCTAACTAGACGTCCCAGAGCTAAAGGCTGGGCAACCCAAATGATAGTC
AGCTAACTAGACGTCCCAGAGCTAAAGGCTGGGCAACCCAAATGATAGTC

Cyclin A promotor
pGLS-CAL RV primer 3

GCCAAAGTTTAATTCCGTTTAATTCCCTAAAAGGCTTAGAGTCAGCCTTC
GCCAAAGTTTAATTCCGTTTAATTCCCTAAAAGGCTTAGAGTCAGCCTTC

**************************************************

Cyclin A promotor
pGLS-CAL RV primer 3

GGACAGCCTCGCTCACTAGGTGGCTCAGCTTAAAATZ^ATCGGAAGCGTCG
GGACAGCCTCGCTCACTAGGTGGCTCAGCTTAAAATAATCGGAAGCGTCG

Cyclin A promotor
pGLS-CAL RV primer 3

GGCCCTAAATCCTACCTCTCCCCGCCCCGCGCAGGCGTTTTCTCCCGCCC
GGCCCTAAATCCTACCTCTCCCCGCCCCGCGCAGGCGTTTTCTCCCGCCC

Cyclin A promotor
pGLS-CAL RV primer 3

CAGCCAGTTTGTTTCTCCCTCCTGCCCCGCCCCTGCTCAGTTTCCTTTGG
CAGCCAGTTTGTTTCTCCCTCCTGCCCCGCCCCTGCTCAGTTTCCTTTGG

Cyclin A promotor
pGLS-CAL RV primer 3

TTTACCCTTCACTCGCCC-TGACCCTGTCGCCTTGAATGACGTCAAGGCC
TTTACCCTTCACTCGCCTGCGACCCTGTCGCCTTGAATGACGTCAAGGCC

Cyclin A promotor
pGLS-CAL RV primer 3

**************************************************

**************************************************

**************************************************

**★★**★*****★★★**

******************************

GCGAGCGCTTTCATTGGTCCATTTCAATAGTCGCGGGATACTTGAACTGC Cyclin A promotor
GCGAGCGCTTTCATTGGTCCATTTCAATAGTCGCGGGATACTTGAACTGC pGLS-CAL RV primer 3

**************************************************

AAGAACAGCCGC-GCTCCAGCGGGCTGCTCGCTGCATCTCTGGGCGTCTT
AAGAACAGCCGCCGCTCCGGCGGGCTGCTCGCTGCATCTCTGGGCGTCTT

Cyclin A promotor
pGLS-CAL RV primer 3

TGGCTCGCCACGCTGGGCAGTGCCTGCCTGCGCCTTTCGCAACCTCCTCG
TGGCTCGCCACGCTGGGCAGTGCCTGCCTGCGCCTTTCGCAACCTCCTCG

Cyclin A promotor
pGLS-CAL RV primer 3

GCCCTGCGTGGTCTCGAGCTGGGTGAGCGAGCGGGCGGGCTGGTAGGCTG
GCCCTGCGTGGTCTCGAGCTGGGTGAGCGAGCGGGCGGGCTGGTAGGCTG

Cyclin A promotor
pGLS-CAL RV primer 3

GCCTGGGCTGCGACCGGCGGCTACGACTATTCTTTGGCCGGGTCGGTGCG
GCCTGGGCTGCGACCGGCGGCTACGACTATTCTTTGGCCGGGTCGGTGCG

Cyclin A promotor
pGLS-CAL RV primer 3

************ ***** *******************************

**************************************************

**************************************************

**************************************************

AGTGGTCGGCTGGGCAGAGTGCACGCTGCTTGGCGCCGCAGGCTGATCCC Cyclin A promotor
AGTGGTCGGCTGGGCAGAGTGCACGCTGCTTGGCGCCGCAGGCTGATCCC pGLS-CAL RV primer 3

**************************************************

gccgtccactcccgggagcagtg
GCCGTCCACTCCCGGGAGCAGTG

***********************

Cyclin A promotor
pGLS-CAL RV primer 3
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CLUSTAL W (1.81) Multiple Sequence Alignment for PAI-1 Promoter
ACATAACCCGGGAGGTACCGAGCTCTTACGCGTGCTAGCTCGAGCAGCTG
ACATAACCCGGGAGGTACCGAGCTCTTACGCGTGCTAGCTCGAGCAGCTG

3TP promotor
pGL3-PAI RV primer 3

•k'k'k'k-kir'k-k-k-k-k-k-k-k-k-k-k-k-k-k-k-k-k-k-k-k-k-k'k'k'k-k-k-k-k-k-k-k-k-k-k-k-k-k-k-k-k-k-k*

AAGCTCCCTTCCAGAAAGCAGAGGTGTCTGACTCATATGAGTCAGACACC
AAGCTCCCTTCCAGAAAGCAGAGGTGTCTGACTCATATGAGTCAGACACC

3TP promoter
pGL3-PAI RV primer 3

■a-*************************************************

TCTGGCTGTCTGGAAGGGATGAGTCAGACACCTCTGGCTTTCTGGAAGGG
TCTGGCTGTCTGGAAGGGATGAGTCAGACACCTCTGGCTTTCTGGAAGGG

3TP promoter
pGLS-PAI RV primer 3

•k'k'k'k'k'k-k-k'k-k'k-k-k^-k-k-k-k-k-k-k-k-k-k-k-k-lc-k-k-k-k-k-^ic-k-k-h-k-k-k-k-k-k-k-k-k-k-k-k-k

AGCTTGCATGCCCTAGAGGATCCAACCTCAGCCAGACAAGGTTGTTGACA 3TP promoter
AGCTTGCATGCCCTAGAGGATCCAACCTCAGCCAGACAAGGTTGTTGACA pGLS-PAI RV primer 3
***********************************************-*-**
CAAGAGAGCCCTCAGGGGCACAGAGAGAGTCTGGACACGTGGGGGGTCAG
CAAGAGAGCCCTCAGGGGCACAGAGAGAGTCTGGACACGTGGGGG-TCAG
'k'k'k'k'k'k'k'k'k'k'k'k-k'k'k-k'k'k'k'k'k-k^'k'k'k-k'k'k-k'k'k'k'k-k-k'k'k'k'k'k'k'k'k'k

•k 'k 'k 'k

CCGTGTATCATCGGAGGATCCCCAGTCCTATATATACTCGCTCTGCACTT
CCGTGTATCATCGGAGGATCCCCAGTCCTATATATACTCGCTCTGCACTT

3TP promoter
pGLS-PAI RV primer 3
3TP promotor
pGL3-PAI RV primer 3

'k-k'k-k-k-k'k'k-k-k-k-k-k-k-k'k-k-k-k-k-k-k-k-k-k-k-k-k-k-k-k-k-k-k-k-k-k-k-k-k-k-k-k-k-k-k-k-k-k-k

GGCCCTTTTTTACACTGTGACTGATTGAGCTGGTGCCGTGTCGGGGTACC
GGCCCTTTTTTACACTGTGACTGATTGAGCTGGTGCCGTGTCGGGGTACC
*********************************************-*-****

3TP promotor
pGLS-PAI RV primer 3

GAGCTCGAATTAGCTTGGCATTCCGGTACTGTTGGTAAA 3TP promotor
GAGCTCGAATTAGCTTGGCATTCCGGTACTGTTGGTAAA pGLS-PAI RV primer 3
'k'k'k'k-k'k'k-k-k'k'k'k'k'k'k-k'k'k^'k'k'k'k-k'k'k'k'k'k'k-k'k-k'k'k'k'k'k'k

Figure 37. Sequence alignment of the PAI-1 promoter region with the promoter of
pGLS-PAI. The PAI-1 promoter region was sequenced using the RV primer 3. The
sequence was aligned with the known PAI-1 promoter (from p3TP-Lux) sequence using
Clustal W multiple alignment method (Biology Workbench 3.2, San Diego Super
Computer Centre).
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